No retraction, correction or concern found when last checked on Oct 19, 2026.

Blood–Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia

Basharat Hussain, Cheng Fang, Junlei Chang

Frontiers in Neuroscience · 2021 · Review · CC BY

doi:10.3389/fnins.2021.688090

Abstract

The blood–brain barrier (BBB) plays a vital role in maintaining the specialized microenvironment of the neural tissue. It separates the peripheral circulatory system from the brain parenchyma while facilitating communication. Alterations in the distinct physiological properties of the BBB lead to BBB breakdown associated with normal aging and various neurodegenerative diseases. In this review, we first briefly discuss the aging process, then review the phenotypes and mechanisms of BBB breakdown associated with normal aging that further cause neurodegeneration and cognitive impairments. We also summarize dementia such as Alzheimer's disease (AD) and vascular dementia (VaD) and subsequently discuss the phenotypes and mechanisms of BBB disruption in dementia correlated with cognition decline. Overlaps between AD and VaD are also discussed. Techniques that could identify biomarkers associated with BBB breakdown are briefly summarized. Finally, we concluded that BBB breakdown could be used as an emerging biomarker to assist to diagnose cognitive impairment associated with normal aging and dementia.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The central nervous system (CNS) comprises the brain and spinal cord that control all the essential functions of the body. The distinctive physiological and anatomical structure of the brain and spinal cord makes the CNS a largely immune-privileged organ (Engelhardt and Coisne,; Ransohoff and Engelhardt, ). Blood vessels are essential to transport oxygen and nutrients, remove CO2 and other waste products, and, thus, maintain homeostasis in the body. Blood vessels that vascularize the CNS acquire specific anatomical and functional characteristics that collectively form the blood–brain barrier (BBB) (Obermeier et al.,; Zhao et al., ).

2At the cellular level, the BBB is developed by continuous non-fenestrated endothelial cells (ECs) encompassed by pericytes, smooth muscle cells, astrocytes, microglia, oligodendroglia, and neurons that are altogether called the neurovascular unit (NVU) (Zlokovic,; Blanchette and Daneman,; Chow and Gu, ). At the molecular level, the BBB ECs are compacted by claudins, occludins, and ZO-1 [tight junction (TJ) proteins] and junction adhesion molecules (JAM) proteins to restrict the paracellular and transcellular diffusion of molecules in the CNS. In addition, the BBB ECs mediate influx transporters to select metabolite uptake from the blood and efflux transporters to remove toxins and waste products from the brain into the blood. In BBB ECs, leukocyte adhesion molecules (LAMs) express very low to suppress immune surveillance in the brain (Quaegebeur et al.,; Engelhardt and Ransohoff,; Chow and Gu,; Xiao et al., ). Thus, the BBB confines the access of neurotoxic compounds, blood cells, and pathogens to the brain (Winkler et al., ). In addition, the BBB sustains the homeostasis of the brain through tight regulation of the transport of molecules between the brain parenchyma and peripheral circulation (Abbott, ). Figure 1A shows the normal BBB.

3Hence, the BBB is a fundamental and crucial element of normal and healthy brain function. Any impairment in the cellular or molecular components causes BBB breakdown that results in BBB dysfunction. Aging is one of several factors involved in the breaking of the BBB and was first observed in aged patients reported in the 1970s (Tibbling et al., ). In dysfunctional BBBs, the possibility of permeability increases; thus, toxic and blood-borne inflammatory substances that infiltrate the brain could change the biochemical microenvironment of the neurons, thus leading to neurodegenerative diseases and dementia (Abbott et al.,; Zeevi et al.,; Zlokovic,; Rosenberg,; Sweeney et al., ). It has been reported that BBB disruption in aged people is strongly related to Alzheimer's disease (AD) and cognitive impairment (Farrall and Wardlaw,; Van De Haar et al.,; Skillbäck et al.,; Zenaro et al.,; Sweeney et al.,; Nation et al., ). Figure 1B shows the impaired BBB.

4In this review, we first briefly discuss the aging process, and then review the phenotypes and mechanisms of BBB breakdown associated with normal aging that further cause neurodegeneration and cognitive impairments. We also summarize dementia such as AD and vascular dementia (VaD); then, we discuss the phenotypes and mechanisms of BBB disruption in dementia correlated with cognition decline. Subsequently, we also discuss the overlap between AD and VaD. Furthermore, we mention biomarkers associated with BBB breakdown during aging and dementia; additionally, we also briefly discuss various techniques to identify BBB biomarkers. Finally, we conclude that BBB breakdown could be used as a novel biomarker to diagnose cognitive impairment associated with normal aging and dementia.

BBB Breakdown in Normal Aging

5The universal process in an organism leads to the cumulation of biological variations responsible for progressively diminishing bodily functions over time, which is known as aging (Kritsilis et al., ). Because of the advancement in medicine and the living standard of humans, life expectancy has doubled worldwide (Aw et al., ). Aged people are estimated to make up approximately 20% of the world population in the next 50 years (Ellison et al., ). In terms of the brain and the BBB, normal aging can be defined as a retrogression in the activities of the body with no cognitive ailment and dementia. Although ailments do not occur in this case, the frequency of age-related diseases increases with the aging process. Alzheimer's, cardiovascular, Parkinson's disease, stroke, and various other neurological diseases commonly occur in aged people (Erdo et al., ). A recent study demonstrated that BBB breakdown could be considered a biomarker for the normal aging process (Verheggen et al., ). Furthermore, BBB breakdown also impairs the influx of nutrients (glucose) and oxygen and efflux of waste products, which may cause hypoxia-associated inflammation (Elahy et al.,; Raja et al., ). Subsequently, age-related BBB pathology makes the brain more susceptible to neuronal impairment and even causes neurodegeneration (Levit et al.,; Banks et al., ). It has been reported that aged people with prior cognitive impairment were more vulnerable to BBB disruption than people with no cognitive dysfunction of the same age; hence, BBB disruption can be considered an early biomarker related to declines in human cognition (Nation et al., ). All these studies show that the way alterations in BBB components progress with time might be an interesting research topic to explore in association with the normal aging brain.

Phenotypes of BBB Breakdown in Normal Aging

6During aging, various changes occur in the structure and function of brain vasculature. In the aged brain, the BBB becomes broken; hence, the permeability of the BBB elevates (Villeda et al.,; Hyman et al., ) and declines in the cerebral blood flow (CBF) occur (Tarumi and Zhang, ). The potency of neovascularization diminishes (Rivard et al.,; Gao et al., ) and the density of capillary of brain vasculature reduces with age (Reeson et al., ). It has been observed that, during aging, BBB breakdown is the first incident that starts in the hippocampus, which may lead to declines in cognition (Montagne et al., ). In normal aging, the main changes that are strongly correlated to BBB breakdown are presented in Table 1.

7It has been reported that, in aging, the brain endothelium becomes progressively dysfunctional, which is correlated with aberrant changes in the BBB (Cai W. et al.,; Edwards et al., ). The extracellular matrix (ECM) of the basal membrane or basal lamina covers the brain endothelium and is considered uniform and thin. In normal aging, the thickness of the ECM increases with the increase in collagen IV and argin but decreases in laminin concentrations (Candiello et al., ). Although the ECM has a role in maintaining BBB integrity by inducing TJ (occludin) protein expression, changes in the ECM cause BBB disruption, and thus result in increased BBB permeability (Hawkins and Davis,; Candiello et al.,; Sanchez-Covarrubias et al., ).

8In the CNS BBB, ECs associated with pericytes, astrocytes, neurons, and glial cells that develop and maintain their specific phenotype led to BBB integrity (Erickson and Banks, ). However, with aging, this association caused BBB breakdown. During aging, physiological ultrastructure changes have been reported in pericytes, such as an increase in mitochondria size (Hicks et al., ), vesicular and lipofuscin-like inclusions (Rascher and Wolburg, ), and foamy transformations (Sturrock, ). In addition, the protrusions on the basal lamina or the ECM membrane of the microvessels have been observed to result in the degeneration of pericytes (Ueno et al., ). A loss of pericytes has also been reported in aging mice, rats, and the human brain (Stewart et al.,; De Jong et al.,; Bell et al.,; Duncombe et al.,; Goodall et al., ) but some studies observed that the number of pericytes increases in aged rat brains (Heinsen and Heinsen,; Peinado et al., ). However, no change was observed in the number of pericytes in aged monkey brains (Peters et al., ).

9Platelet-derived growth factor receptor beta (PDGFRβ) maintains the phenotype of pericytes in the brains of aged mice with PDGFRβ+/−, which shows that the loss of pericytes leads to BBB breakdown and increased BBB permeability (Bell et al., ). It has been reported, in the aged human brain, the level of soluble PDGFRβ in cerebrospinal fluid (CSF) increases, showing damage to the pericyte associated with BBB disruption (Montagne et al.,; Sagare et al.,; Nation et al., ). In addition, it has been reported that, in APOE4 carriers, the elevated PDGFRβ in the CSF may be used as a biomarker of cognitive impairment (Montagne et al., ).

10The endfeet of astrocytes that ensheath the pericytes have a contribution to BBB development and maintenance. With the age, vascular coverage and aquaporin-4 (AQP4) expression of astrocyte endfeet are reduced whereas glial fibrillary acidic protein (GFAP) expression and endfeet sizes are increased (Middeldorp and Hol,; Duncombe et al.,; Goodall et al., ), leading to increase in reactive astrogliosis.

11Microglia are distributed ubiquitously in the CNS and activated during aging and pathology (Kettenmann et al.,; Kofler and Wiley,; Harry,; Sanchez-Covarrubias et al., ). Microglia have a ramified structure in the resting state, but when activated, this structure changes into an amoeboid morphology during aging or a pathophysiological state (Kettenmann et al., ). During aging or stress, the activated microglia produce tumor necrosis factor-α (TNF-α), proteases, nitric oxide (NO), and peroxide (Ronaldson and Davis, ), which are associated with an alteration in the TJ protein. This alteration induces BBB leakage (Huber et al., ), which, in turn, leads to cell injury and neurodegeneration (Ronaldson and Davis, ).

12Studies have shown that neurons directly connect with brain ECs and astrocytes (Ben-Menachem et al.,; Cohen et al.,,; Tong and Hamel,; Vaucher et al.,; Sanchez-Covarrubias et al., ). Impairment in this association results in BBB breakdown and leads to an increase in BBB permeability to albumin (Berezowski et al., ). Figure 1 shows the difference between young or normal BBB and aged or dysfunctional BBB.

Mechanisms of BBB Breakdown During Normal Aging

13During aging, various mechanisms cause BBB breakdown and increase BBB permeability. For example, in aging, oxidative stress induces ECs to produce TNF-α that cause the degradation of the basement membrane, and TJs (Occludin, Zonula occludins-1), which, in turn, results in BBB disruption and an increase in BBB permeability (Donato et al.,; Bake et al.,; Lee et al.,; Elahy et al.,; Cai W. et al., ). In addition, the activity of caspase 3/7 in the aged brain increases, which causes the suppression of cell viability and the upregulation of apoptosis in pericytes (Schultz et al., ), resulting in the reduction of the number of pericytes in the BBB (Bell et al., ). The senile pericytes produce NO and react with O2, causing increased oxidative stress and compromised BBB integrity (Hughes et al.,; Sweeney et al.,; Cai W. et al., ). Similarly, in aging, oxidative stress enhances astrocytes to upregulate the expression of cytokines and chemokines, such as matrix metalloproteinase 3 (MMP3) and p16INK4A [senescence-associated secretory phenotype (SASP)], that induce BBB disruption, neuroinflammation, and cognitive impairments (Simpson et al.,; Salminen et al.,; Cai Z. et al.,; Bussian et al., ). In aging, oxidative stress also activates the microglia to release cytokines, chemokines IL-6, IL1ß, and TNF-α, which results in the elevation of reactive oxygen and nitrogen species; this ultimately causes the breakdown of the BBB (Gredilla et al.,; Choi et al.,; Fivenson et al., ). With age, oxidative stress causes the production of reactive oxygen species (ROS) to elevate in the CNS, but the capability of neurons to clear ROS decreases, resulting in neurodegeneration (Nicholls and Budd,; Mattson and Magnus, ). Furthermore, with age, calcium dysregulation in neurons occurs, which represses calcium-binding proteins correlated with the elevation of ROS. This results in BBB degradation and neuronal loss (He et al., ) as shown (Figure 2).

14Once the BBB integrity becomes compromised, blood-derived proteins such as fibrinogen and plasminogen cross the BBB, and the pro-inflammatory fibrin aggregates in the brain (Cortes-Canteli et al., ). A study using a mouse model showed that accumulated fibrin bind with CD11b/CD18 and activate microglia, which then triggers a decline in cognition (Merlini et al., ). Accumulated fibrin in brain also induce increased ROS level and activates nicotinamide adenine dinucleotide phosphate (NADPH oxidase), which upregulates pro-inflammatory gene expression and causes damage to neuronal axons (Ryu et al.,; Merlini et al., ). In addition, fibrinogen phosphorylates Smad 1/5/8 represses oligodendrocyte progenitor cells (OPCs) (Ryu et al., ). Furthermore, the complex of Aβ-fibrinogen activates microglia via CD11b/CD18, which inhibits the breakdown of fibrinogen and promotes neuronal degeneration (Cortes-Canteli et al.,; Zhao et al., ) as shown (Figure 3A).

15The tissue-type plasminogen activator (tPA) binds and activates low-density lipoprotein receptor-related protein-1 (LRP-1) on ECs. In run, these ECs produce pro-MMPs (MMP-2, MMP-3, and MMP-9) (Wang et al.,; Cheng et al.,; Suzuki et al., ). Subsequently, tPA converts the surface-bound inactive plasminogen (Plg) into active plasmin (Plm) (Doeuvre et al.,; Yepes et al., ). Plasmin, in turn, activates the MMPs, leading to the degradation of TJs and basal lamina (Mazzieri et al.,; Ramos-DeSimone et al.,; Monea et al.,; Rosenberg and Yang,; Yang Y. et al., ). Furthermore, tPA also binds with LRP-1 on astrocytes, which induces plasmin-mediated activation of Rho kinases and retracts the endfeet of the astrocytes from the blood vessel wall, thus resulting in BBB dysfunction (Niego et al., ). In addition, a study suggested that plasminogen might regulate brain inflammation during AD (Baker et al., ) as shown (Figure 3B).

16Human brain ECs continuously produce complement regulatory proteins and components (Wu et al., ), which are elevated by CNS injury or infiltration into the brain when the BBB is dysfunctional. However, at a young age or in a normal state, complement proteins mostly do not cross the BBB (Hoarau et al.,; Veerhuis et al., ). Once the complement proteins cross the compromised BBB, they could alter the functions of the microglia, oligodendrocytes, and neurons (Orsini et al., ). Complement activation produces C3a and C5a that interact with C3aR and C5aR1, respectively, which play a significant role in the infiltration of inflammatory cells into the brain and the induction of cytokine cascades (IL-1, TNF-α, IL-6, IL-8, IL-17) subsequently leading to neurodegeneration (Jacob and Alexander,; Alexander, ). In AD, amyloid-beta (Aβ) activates the complement signaling by binding to C1q. Inhibition of the C5/C5aR1 pathway was also reported to be a protective therapeutic target in AD (Fonseca et al., ) as shown (Figure 3C).

BBB Breakdown in Dementia (Including AD and Vascular Dementia)

17Dementia is a group of conditions or disorders that affect the functions of the brain. It is a progressive neurological disease associated with impairments in cognition and deterioration of the everyday life activities of an affected individual (Mills et al.,; Kirshner, ). In dementia, BBB breakdown and cerebral hypoperfusion cause brain damage and a decline in cognition (Nation et al.,; Tayler et al., ). Dementia is a considerable health complication affecting millions of people worldwide. In developed countries, AD and VaD are two significant types of dementia with a prevalence of about 4.4 and 1–2%, respectively (Ray et al., ), with AD being the most common type of dementia in aged people (Ballaed et al.,; Hyman et al., ). The World Alzheimer Report 2018 estimated that approximately 50 million people of the global population suffer from dementia, which can increased to 82 million in 2030 and triple to 152 million by 2050 (Patterson, ). Alzheimer's is considered to account for 60–70% of all dementia cases worldwide (Leng and Edison, ). As the BBB has vital contributions to maintaining the microenvironment of the CNS, any impairment in the cellular or molecular components of the BBB can cause various neurodegenerative diseases, including AD (Zlokovic,; Erickson and Banks,; Zenaro et al., ). After AD, VaD is the second most common type of dementia, accounting for 15% of all dementia cases worldwide (O'Brien and Thomas, ). Vascular dementia is a type of neurological disease with a defect in cognition caused by impairment in the vascular system, such as a reduction in CBF (Sabayan et al., ). Various vascular pathologies are associated with VaD, such as infarcts and white matter (WM) alterations (O'Brien and Thomas, ). In addition, brain hemorrhage, ischemia, and hypoxia may be the causing factors of VaD (Kirshner,; Grinberg and Heinsen, ).

Pathophysiology of AD

18Aging is responsible for pathophysiological changes that aggravate neurological diseases. It causes the thickening of the wall of the blood vessel and increases blood vessel tortuosity, which may lead to BBB disruption (Rosenberg, ). The BBB breakdown in AD results in the accumulation of insoluble extracellular plaques of β-amyloid (Aβ) along the walls of blood vessels and causes inflammation in the NVU (Kinnecom et al.,; Kang et al., ). In neuronal cytoplasms, the accumulation of neurofibrillary tangles (NFT) of P-tau is also associated with AD (Kang et al., ). It has been observed that, in AD, the reduction of Aβ clearance is correlated with declines in CBF and cognitive impairment (Sagare et al., ). These pathological markers are associated with BBB impairment, which causes microglial activation, neuroinflammation, degeneration of neurons, and cognitive impairment (Bhaskar et al.,; Iadecola, ). As pericytes have a crucial role in the development and maintenance of BBB, their number and density decreased in the cortex and hippocampus of AD patients (Sengillo et al., ), subsequently leading to the upregulation of the expression of Aβ and p-tau protein (Sagare et al., ).

19Vascular (stroke, hypertension, diabetes, etc.) and genetic factors (APOE4) are two pathways that cause BBB impairment and oligemia (reduced CBF) that result in dementia. In the Aβ-independent pathway (blue), the BBB breakdown causes a release of neurotoxins from one side and leads to CBF reduction on another side. In the Aβ-dependent pathway (green), the BBB breakdown impairs the clearance of Aβ and APP (amyloid precursor protein), leading to the aggregation of Aβ in the brain. The accumulated Aβ and vascular hypoperfusion phosphorylate tau, leading to the formation of NFTs. In addition, the deposited Aβ also cause inflammation in the brain. In conclusion, both factors and pathways cause neurodegeneration leading to dementia (AD) (Iadecola and Davisson,; Jack,; Winkler et al.,; Sagare et al.,; Edwards et al., ) as shown (Figure 4).

Phenotypes of BBB Breakdown in AD

20In AD patients, the BBB is shown as leakages in brain vasculature, the perivascular aggregation of fibrinogen, albumin, thrombin, and immunoglobulin (IgG), the loss of TJs, and the degeneration of ECs and pericytes (Nelson et al., ). Furthermore, identical phenotypes were also observed in Apoe−/− mice due to BBB impairment (Nishitsuji et al.,; Bell et al.,; Hammer et al.,; Soto et al.,; Castillo-Gomez et al.,; Di Cataldo et al., ), indicating that ApoE is vital for maintaining BBB integrity.

21As pericytes are crucial for maintaining the BBB, any dysfunction in the signaling pathways of pericytes results in the breakdown of BBB, which causes dementia and other neurodegenerative diseases (Sagare et al.,; Nikolakopoulou et al., ). Brain microvascular endothelial cells (BMEC) secrete platelet-derived growth factor BB (PDGF-BB) and activate PDGFRβ signaling, which is essential for the proliferation, migration, and survival of pericytes (Stratman et al., ). An impairment in PDGFRβ signaling leads to pericyte degeneration (Stratman et al.,; Nation et al., ). According to a previous study, PDGFRβ signaling was decreased in adult Foxf2 deficient mice, thus resulting in high BBB permeability (Reyahi et al., ). Impairment in the BBB was also reported in Pdgfrβ+/− pericyte-deficient mice, which subsequently caused neuronal degeneration (Bell et al., ). In the AD murine model (APPsw/0), the deterioration of pericytes results in the dysfunction of the BBB, leading to amyloid β accumulation and tau protein (p-tau) phosphorylation (Sagare et al., ). The breakdown of the BBB was also reported in AD patients associated with the reduction in pericytes (Sengillo et al., ). Studies also showed that the leakage of the BBB in AD patients starts at the hippocampus, resulting in an increase of soluble PDGFRβ (sPDGFRβ) in the CSF (Montagne et al.,; Miners et al., ). Additionally, the level of sPDGFRβ in the CSF can be used as a biomarker to predict dementia and other neurodegenerative diseases such as AD (Nation et al., ).

22Astrocytes are one of the main components of the NVU and are essential for the integrity of the BBB. In an in vitro study, it was observed that Sonic hedgehog (Shh) signaling released from astrocytes plays a vital role in the maintenance of BBB integrity by upregulation of CLDN5 and OCLN (Alvarez et al.,; Wang et al., ). Recently, it was also reported that, in the stroke mouse model, ischemia-induced astrogliosis led to the downregulation of the expression of TJ protein claudin-5 and occludin (Matthes et al., ), suggesting that astrocytes have a role in the regulation of TJ proteins. Another recent study reported that, in the tamoxifen-induced astrocyte ablation adult mouse model, the expression of TJ protein ZO-1 was downregulated in vessel regions where astrocyte loss occurred, which may show the role of astrocytes in maintaining the integrity of the BBB in adult brains (Heithoff et al., ). A conditional knockout mouse study also showed that the deletion of laminins in astrocytes caused a decline in astrocytic AQP4 (Aquaporin4) expression, thus leading to a loss of TJ in ECs (Yao et al., ). In the AD brain, various changes in the morphology of astrocytes have been reported to cause BBB breakdown (Cai Z. et al., ). The depolarization of astrocyte endfeet may diminish the integrity of BBB, which was reported in the tg-ArcSwe mouse model of AD(Yang J. et al., ). In AD models, researchers also identified several changes in the morphology of astrocytes endfeet near aggregated vascular Aβ (Kimbrough et al., ).

23A mouse study showed that microglia stimulate TJ protein claudin-5 expression and maintain BBB integrity (Haruwaka et al., ). However, the BBB integrity becomes compromised with prolonged inflammation through the changing of the morphology of microglia (Lassman et al.,; Haruwaka et al., ). In the AD brain, due to the accumulation of Aβ, microglia activate and secret inflammatory cytokines, such as interleukins (IL-1 and IL-6) and tumor necrosis factor (TNF-α, and TNF-β) (Zhou et al., ) that cause BBB impairment (Wang et al., ). As a result, the trafficking of neutrophils through the BBB becomes elevated due to BBB breakdown (Allen et al.,; Wang et al.,; Zenaro et al., ). Furthermore, it has been observed that, in the tamoxifen-induced astrocyte knockout adult mouse model, the loss of astrocytes causes the activation of microglia (Heithoff et al., ); in turn, the activated microglia produce reactive oxygen and reactive nitrogen species (RNS), leading to BBB dysfunction and neurodegeneration (Block,; Sumi et al., ).

24In the physiological state, perivascular macrophages (PVMs) have a significant role in the maintenance of TJs between ECs. They also decrease vessel leakage, degrade pathogens, and limit inflammation (Lapenna et al., ) while contributing to BBB breakdown in the disease state (Boyle et al., ). These PVMs are enriched with scavenger receptors, might be involved in the clearance of toxin products from the brain parenchyma (Faraco et al., ), and have a diverse role in disease states such as AD (Lapenna et al., ). Perivascular macrophages have been shown to phagocytose and alleviate Aβ plaques, and the PVM-deficient mouse model showed an increased aggregation of Aβ42 and cerebral amyloid angiopathy (CAA) related with AD (Yang et al., ). Another study showed that PVMs that are deficient in CD36 and Nox2 abrogated the production of ROS and Aβ cerebrovascular impairment compared with wild-type mice (Park et al., ).

25In addition, perivascular fibroblasts (FBs) express the ECM genes col1a2 and col5a1 and are considered to mediate blood vessel integrity. Zebrafish deficient with col5a1 showed spontaneous hemorrhage in the presence of the additional genetic ablation of the col1a2 gene, suggesting the role of perivascular FBs in stabilizing vascular integrity (Rajan et al., ). Perivascular FBs also express Lama2, Lamb1, and Lamc1, which encode laminin 211 that interacts with astrocytic dystrophin, resulting in the regulation of AQP4 in astrocytic endfeet. This study suggests that any impairment in perivascular FBs result in the dysregulation of AQP4, which may cause Aβ aggregation and AD as reviewed by Lendahl et al.. Furthermore, it has been reported that alteration in the activity of perivascular FBs also leads to other neurological disorders (Månberg et al., ).

Mechanisms of BBB Breakdown in AD

26Various pathological and aberrant events such as oxidative stress, inflammation, and the ApoE4 genotype cause BBB breakdown associated with AD. Research has shown that, in AD, the activation of the inflammatory and oxidative stress signaling pathways is the primary event that causes BBB disruption (Perry et al.,; Candore et al.,; Eikelenboom et al., ). Cytokines (Pan et al., ), Aβ (Gonzalez-Velasquez et al.,; Deli et al.,; Carrano et al., ), LPS (Bannerman and Goldblum,; Verma et al., ), and p-tau proteins (Kovac et al., ) are the stimulus of inflammation for the activation of inflammatory pathways in BBB ECs. Hence, increases of the pro-inflammatory mediators and ROS/RNS in BBB ECs, astrocytes (Tada et al., ), and pericytes (Kovac et al.,; Takata et al., ) ultimately cause BBB breakdown. Recently we reviewed the role of peripheral inflammation in BBB breakdown (Huang et al., ). Glucose transporter protein (GLUT1) is repressed in the endothelium of AD, which causes a decline in the glucose level of the CNS (Mooradian et al.,; Winkler et al., ). In human AD, LRP1, which is a primary receptor for the clearance of amyloid-β, is downregulated with an increase in oxidative stress (Deane et al.,; Donahue et al.,; Sagare et al.,; Miller et al.,; Owen et al.,; Halliday et al., ); as a result, the transport of Aβ from the brain becomes reduced and leads to amyloid-β accumulation in the brain (Deane et al.,,; Storck et al., ). In mice, systemic inflammation with LPS has been observed to downregulate both LRP-1 and P-gp efflux transporters and block the Aβ clearance from the brain (Jaeger et al.,; Erickson et al., ). Furthermore, it has been reported that the expression levels of the receptor for advanced glycosylation end products (RAGE) in both mural cells and brain endothelium were elevated (Deane et al.,; Donahue et al.,; Miller et al., ). The function of the RAGE is to transfer Aβ from blood to the brain (opposite to LRP1), which enhances neuronal inflammation. In AD patients, the RAGE is observed as a significant therapeutic target (Bell et al., ). A transgenic mouse with overexpressed APP (amyloid precursor protein) has been reported to show vascular impairment due to the elevation of Aβ40 (Niwa et al., ).

27Aquaporin-4 (AQP4) is the prime water channel expressed in the CNS and is primarily expressed in astrocytes, thus playing a vital role in normal brain homeostasis and various neurological diseases (Lan et al., ). Specifically, AQP4 facilitates the clearance of Aβ, and alteration in AQP4 expression leads to the accumulation of amyloid-β in the brain (Hoshi et al.,; Yang et al., ). Furthermore astrocytic AQP4-deficient animals cannot efficiently remove Aβ from the brain (Iliff et al., ). A study showed that AQP4 is crucial to regulate fluid flow in the brain interstitial required to maintain the microenvironment for neurons to function properly. The perturbed AQP4 expression has been observed to cause Aβ deposition and inflammation in the human brain, which leads to AD (Rasmussen et al., ). In AD patients and animal models, the expression and distribution of AQP4 were altered, leading to amyloid-β accumulation, which plays a vital role in the pathogenesis of AD as reviewed by Yang et al.. Furthermore, it has been observed that, in AD patients, the localization of AQP4 in the perivascular space was reduced and is associated with an increase in neurofibrillary and amyloid-β pathology (Zeppenfeld et al., ). In addition, AQP4 facilitates the transport of potassium and calcium ions, which plays an essential role in the pathogenesis of AD as reviewed by Lan et al.. In AD, the chronic activation of microglia leads to the release of abundant pro-inflammatory cytokines and abolishes phagocytosis, thus causing the deposition of Aβ and neuroinflammation (Krabbe et al.,; Heneka et al., ) and subsequently producing ROS that causes BBB dysfunction and neurotoxicity (Block,; Sumi et al., ). The activated microglia also release IL-1β (a pro-inflammatory cytokine) that amplify the BBB leakage and diminish the ability of the astrocytes to maintain the BBB (Wang et al., ). Therefore, AQP4 can be a fascinating therapeutic target for AD and other CNS diseases.

28Apolipoprotein E (ApoE) is a protein encoded by the APOE gene, located on chromosome 9 and associated with lipid transport. APOE consists of three alleles, namely, ε2, ε3, and ε4, translated to ApoE2, ApoE3, and ApoE4 isoforms. The APOE isoform distributed as APOE3 is the most abundant in humans at approximately 77.9%, while APOE4 and APOE2 distributions are 13.7 and 8.4%, respectively (Farrer et al., ). In the CNS, astrocytes produce ApoE, whereas, in peripheral tissue, ApoE production occurs in the liver (Liu et al., ).

29Studies reported that ApoE plays an essential role in maintaining BBB integrity (Nishitsuji et al., ). An in vivo study showed that ApoE2/3 induces BBB integrity by interacting with LRP-1 on pericytes to block the cyclophilin-A nuclear factor kβ matrix metalloproteinase 9 (CypA-NF-kβ-MMP-9) pathway, thus resulting in the inhibition of MMPs (Bell et al., ). Researchers also observed that the APOE4 isoform is a major risk factor for AD, and that the binding of Aβ with apoE4 shifts fast clearance of soluble Aβ40/42 from LRP1 to VLDLR; hence, Aβ-apoE4 complexes at the BBB are cleared with a slower rate than LRP1 (Deane et al.,; Tachibana et al., ). The expression of APOE4 causes a reduction in BBB integrity by promoting pericyte degeneration in AD (Bell et al., ), which is correlated with high BBB permeability to IgG and fibrin (Halliday et al., ). In a transgenic mouse study, the mice that had Apoe replaced with human APOE (TR-APOE) showed astrocytes that secreted ApoE4 blocks pericytic LRP-1, resulting in the activation of the proinflammatory CypA-NF-kB MMP9 pathway, BBB disruption, and brain hemorrhage through the enzymatic breakdown of the TJ and basement membrane (Nishitsuji et al.,; Bell et al., ). A study showed that an LRP1 endothelial knockout caused the activation of the CypA–MMP9 pathway in the endothelium, which led to damage to TJs and BBB breakdown (Nikolakopoulou et al., ). In TR-APOE4 mice, the repression of Glut1 and upregulation of RAGE expression were also observed compared with TR-APOE3 or TR-APOE2 (Alata et al., ). It has been reported that humans carrying APOE4 are more prone to breakdown in the BBB and loss of pericytes than non-APOE4 carriers (Hultman et al.,; Zonneveld et al.,; Halliday et al., ). Furthermore, CypA and MMP-9 levels increase in APOE4 carriers, leading to the elevation of IgG and fibrinogen leakages (Halliday et al., ). Overall, these results suggest that ApoE2/3 represses inflammation by interacting with pericyte LRP-1, subsequently inducing BBB integrity. In contrast, the ApoE4 might have BBB impairment properties or cause a higher risk of BBB breakdown. The repression of ApoE4 or inhibition of the CypA–MMP9 pathway in humans with AD might be an exciting topic in the future for the reduction the neurodegenerative process (Figure 5).

BBB Breakdown in VaD

30Vascular dementia is a neurodegenerative disease caused by reduced CBF to the brain resulting in cognitive dysfunction. After AD, VaD is considered the second most common dementia, accounting for ~15–30% of all dementia (Sloane et al.,; Abou-Saleh et al.,; Gorelick et al.,; Goodman et al., ).

Pathophysiology of VaD

31Chronic hypoperfusion and thrombosis are the main factors in VaD that cause reduced CBF and promote oxidative stress, hypoxia, and inflammatory molecule expression (cytokines/chemokines). These chronic events cause damage to the periventricular WM, basal ganglia, and hippocampus. Cerebrovascular pathology has a significant contribution to the pathogenesis of VaD by damaging the brain. Vascular impairments include large vessel atherosclerosis (AS), small vessel AS, and CAA. These cerebrovascular pathologies cause microinfarcts in gray matter, WM lesions, and microbleeds (Thal et al., ). These vascular abnormalities can occur throughout the brain, resulting in VaD (Grinberg and Heinsen, ).

Phenotypes of BBB Breakdown in VaD

32Hypertension is one of the factors that cause BBB breakdown in VaD with the accumulation of perivascular collagen in the hippocampus and WM lesions (Verhaaren et al., ). Toxic molecules or high blood pressure cause damage to the BBB endothelium. Hypertension also causes a reduction in the integrity of ECs and pericytes, astrocytes endfeet swelling, and retraction from the vessel wall, which results in BBB breakdown and subsequently leading to a reduction in CBF (Wardlaw et al., ). Studies reported that acute ischemia induces BBB permeability by the secretion of ROS (Abboud et al.,; Simpkins et al., ). A study also showed that, during vascular pathology, chronic hypoperfusion causes BBB disruption in WM lesions (Tomimoto et al., ). Another study showed that BBB disruption due to the degeneration of pericytes results in the disruption of WM circulation, deposition of fibrinogen, and reduction of CBF that further induces damage to the myelin, axons, and oligodendrocytes (Montagne et al., ) (Figure 6). Furthermore, animal experiments showed that chronic cerebral hypoperfusion (CCH) increases BBB leakage to intravenously injected horseradish peroxidase (HRP) in the corpus callosum. In animals, perivascular collagen was also accumulated in the corpus callosum associated with WM lesion formation and elevated BBB permeability (Ueno et al., ). In VaD, PVMs have been reported to induce oxidative stress leading to hypertension (Yang et al., ).

Mechanisms of BBB Breakdown in VaD

33Hypoxia upregulates oxidative stress, which produces NO, ROS, and free radicals (Li et al.,; Ma et al.,; Zhang et al., ). In addition, oxidative stress disrupts the ratio of antioxidants, NO, and ROS and causes damage to the endothelial, glial, and neuronal cells, resulting in the impairment of the NVU, BBB disruption, and mediation of a reduction in CBF (Liu and Zhang, ). In particular, ROS can further lead to mitochondrial dysfunction resulting in cerebral hypoxia that induces oxidative stress (Zhang et al., ). Cerebral vascular hypoxia produces inflammatory molecules that cause apoptosis and impairments in the function of microvessels. The cytokines/chemokines cause damage to the endothelium, glial, and neurons cells and, hence, enhance BBB permeability (Gill et al., ). The inflammatory molecules such as IL-1, IL-6, MMPs (MMP-2, MMP-9), TNFα, and TLR4 (toll-like receptor 4) infiltrate the brain (Li and Lai,; Gill et al.,; Candelario-Jalil et al.,; Reuter et al., ), cause demyelination, and damage the axons and oligodendrocytes associated with the hippocampus and WM lesions (Chen et al., ).

34Damage to oligodendrocytes represses remyelination (Ihara et al., ), and demyelination retains the transmission of neural signals, thus resulting in cognitive impairment. Overall, hypoxia, oxidative stress, and inflammation cause defects in neurogenesis, impairment in the proliferation of neuronal progenitor cell, synaptic plasticity, and reduced spine density in the hippocampus, thus resulting in cognitive impairment (Stranahan et al.,; Park et al., ) (Figure 6). Furthermore, several studies reported that CCH causes AD and VaD (Du et al., ). It has also been reported that intercellular adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1) were significantly upregulated in the vascular ECs of the CCH animal model associated with cognitive impairment (Won et al.,; Khan et al., ).

Overlap Between Alzheimer's and Vascular Dementia

35As discussed above and in other studies, significant clinical heterogeneity has been shown between AD and VaD (Sachdev et al.,; Chui and Ramirez-Gomez, ); however, recent studies reported that these two diseases co-occur in what is called mixed dementia (Emrani et al., ). In mixed dementia, vascular pathology not only mediates AD progression, but the pathology of AD also potentiates vascular impairments, suggesting that pure AD or VaD rarely occur (Emrani et al., ). In addition, another study reported that, in aged individuals, there is genetic overlap between vascular dysfunction and AD that is primarily associated with apolipoprotein E (Lin et al., ).

36Community and epidemiological studies reported the mixed neuropathology that is quite common in both AD and VaD (Schneider et al.,; Wharton et al., ). The clinical study observed that only 9% of 1,000 patients with cognitive impairments have pure AD pathology; however, AD pathology is mainly associated with vascular dysfunction or other neurodegenerative diseases (Boyle et al., ). Another clinical study examined 63 patients with mild cognitive impairment (MCI), in which only 28% were reported as pure AD and approximately 24% were diagnosed with mixed dementia (AD and VaD) (Silbert et al., ). Researchers observed that frontal lobe lesions and vascular pathology, e.g., white matter hyperintensities (WMH), are associated with neuropsychiatric symptoms and are common in both AD and VaD (Anor et al., ). Alzheimer's disease and VaD share many similar clinical pathologies that lead to cognitive impairment and neuropsychiatric symptoms associated with behavioral alterations (Kalaria, ) as shown in Table 2. Hence, these studies suggest that there might be considerable overlaps between AD and VaD, and comprehensive studies should be considered to understand the pathophysiology of dementia instead of segregating AD from VaD.

Biomarkers Associated With BBB Breakdown

37Various imaging techniques and other methods are currently being used to identify biomarkers associated with BBB breakdown in different neurological disorders, which are helpful in healthcare decisions. However, during the acute phase of BBB disruption, some of the clinical care places may lack the facilities to perform MRIs; hence, the detection of peripheral blood biomarkers is the best approach to identifying the status of BBB.

38Studies showed that, while the blood/CSF albumin ratio can be used as a biomarker to detect BBB permeability, it cannot distinguish BBB and blood-CSF permeability nor locate leakage as reviewed by Farrall and Wardlaw. Hence, nowadays, the dynamic contrast-enhanced MRI (DCE-MRI) technique is used to directly identify and localize these elusive permeability values (Raja et al., ). A study in healthy, aged individuals using DCE-MRI with a gadolinium-based contrast agent injected intravenously identified that BBB leakage was high and localized in the brain regions most vulnerable to damage from aging (Verheggen et al., ). It has been observed that, by using DCE-MRI, the BBB permeability index Ktrans was increased in the hippocampus and some of its sub-regions, CA1 and dentate gyrus (DG), but not in CA3. This study showed that, in the hippocampus, the BBB integrity was lost progressively with age. Still, no significant BBB leakage was observed in the cortical and sub-cortical regions (Montagne et al., ), suggesting that, in terms of aging, the BBB breakdown starts in the hippocampus. A study using CSF biomarkers and the DCE-MRI technique reported that aged people with prior cognitive impairment had higher BBB permeability than healthy individuals (Nation et al., ). These studies suggest that it is possible to detect and localize BBB leakage by using DCE-MRI.

39It has been observed that, in epileptic patients, the levels of serum Visinin-like protein 1 (sVILIP-1) and serum caveolin 1 (sCAV-1) are higher, which may be used as biomarkers for the diagnosis of BBB breakdown (Tan et al., ). Another protein biomarker is s100β, which is produced by astrocyte endfeet; when the BBB becomes compromised, s100β is immediately released into the peripheral blood (Kadry et al., ). Furthermore, a study identified that the expression levels of A-kinase anchoring protein 7 (AKAP7) were high in the peripheral blood (lymphocyte), and thus might be considered to identify BBB breakdown during ischemic stroke or post-stroke (O'Connell et al., ). Neuron-specific enolase (NSE) and GFAP are also promising biomarkers that can be detected in the CSF to identify BBB breakdown (Kadry et al., ). A study reported that the elevated level of sPDGFRβ is associated with damage to the pericytes and BBB disruption leading to a decline in cognition (Sweeney et al., ). Soluble PDGFRβ as a biomarker was also observed in VaD (Iadecola,; Sweeney et al., ) and various other neurological diseases (Sweeney et al.,, ). Soluble cell adhesion molecules (CAMS), zonulin, and soluble 4-1BBL (transmembrane protein receptor) have also been identified to be associated with BBB damage. PECAM-1, P-selectin, and E-selectin are soluble adhesion molecules reported to be upregulated in individuals with compromised BBB and can be used as biomarkers for BBB breakdown (D'Ambrosio et al., ). Increased leakage of gadolinium (DCE-MRI; Ktrans), microbleeds (T2*-weighted and SWI-MRI), reduced glucose transport (FDG-PET), diminished P-glycoprotein 1 function (verapamil-PET), and CNS leukocyte infiltration (MMP inhibitor-PET) are some of the techniques that can be used to identify biomarkers associated with BBB damages in various CNS diseases (Sweeney et al., ).

Conclusions and Future Directions

40The BBB consists of a set of physiological properties that tightly regulate the normal microenvironment essential for proper neuronal activities. Any impairment in these properties either at the cellular or molecular level causes BBB breakdown. Aging is one of the factors that contribute to BBB disruption. During aging, the various physiological properties of the BBB are impaired, leading to BBB dysfunction. The neurotoxins infiltrating the brain can also cause cognitive impairments and neurodegeneration. Furthermore, BBB breakdown also contributes to dementia that includes ADs and VaD. In AD with disruption of BBB, Aβ and NFT of p-tau accumulate in the blood vessel, causing further inflammation in the NVU that, in turn, induces the release inflammatory factors to degenerate neurons associated with a decline in cognition. Another factor that degrades the integrity of BBB associated with AD is APOE4. In dementia, VaD accounts for the most cases next to AD caused by BBB breakdown. In VaD, the CBF is reduced and inflammatory molecules infiltrate the brain due to BBB impairment, subsequently causing neuronal loss and, thus, cognitive impairment. Hence, BBB breakdown can be used as a novel biomarker to study various neurological impairments such as AD, VaD, and other associated declines in cognition.

41Recently, RepSox was identified to inhibit TGF-B, VEGFA, and inflammatory gene networks (Roudnicky et al., ). Furthermore, RepSox significantly elevated BBB resistance, induced TJs and transporters, reduced paracellular permeability by activating Notch and Wnt pathways, and, thus, might be used as an emerging BBB therapeutics to treat neurological diseases such as AD (Roudnicky et al., ). In addition, secreted protein acidic and rich in cysteine (SPARC) was identified to decrease transendothelial electrical resistance (TEER) and TJ proteins (ZO-1, OCLN) and increase paracellular permeability by regulating the tyrosine kinase pathway (Alkabie et al., ). Hence, the SPARC–collagen binding domain might be a potential therapeutic target to treat AD (Pilozzi et al., ). Furthermore, SPARC/Hevin normalization may also be considered as a novel therapeutic target for the modulation of AD progression (Strunz et al., ).

42Although researchers have reported the contributions of BBB disruption to the pathogenesis of cognitive impairment associated with normal aging and dementia, more research is needed to elucidate the precisely causing factors and the cellular and molecular mechanisms of BBB maintenance, breakdown, and repair correlated with neurodegeneration and cognition decline. In the future, how aging and dementia affect BBB function in health and disease state, thus leading to neurodegeneration and cognitive impairment, should be explored in living organisms. Clinical research pertaining to this will boost our knowledge and help us better understand the association between BBB breakdown and cognitive decline. Such studies pave the way for the use of the BBB as a novel biomarker and therapeutic target to treat dementia and other neurological diseases associated with cognitive impairment. Furthermore, these studies suggest that amelioration in the cerebrovascular pathways (particularly BBB breakdown) can alleviate neurodegeneration in dementia (particularly AD) associated with cognitive impairment. Hence, the characterization of the cellular and molecular constituents of the cerebrovascular systems that contribute to the pathophysiology of dementia will provide a systematic methodology of dementia diagnosis. More profound knowledge of the vascular system will also help design emerging efficient strategies that can be used for the therapeutic interventions of cognitive impairment and dementia.

Author Contributions

43BH drafted the manuscript and made the figures and table. CF and JC discussed and revised the manuscript. All authors contributed to the article and approved the final manuscript.

Conflict of Interest

44The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

45All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 312

1.
Abbott N. J. (2013 ). Blood-brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36, 437–449.
Not in our library10.1007/s10545-013-9608-0
2.
Abbott N. J. Patabendige A. A. Dolman D. E. Yusof S. R. Begley D. J. (2010 ). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25.
Not in our library10.1016/j.nbd.2009.07.030
3.
Abbott N. J. Rönnbäck L. Hansson E. (2006 ). Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53.
Not in our library10.1038/nrn1824
4.
Abboud H. Labreuche J. Meseguer E. Lavallee P. C. Simon O. Olivot J.-M.. (2007 ). Ischemia-modified albumin in acute stroke. Cerebrovasc. Dis.23, 216–220.
Not in our library10.1159/000097644
5.
Abou-Saleh M. T. Katona C. L. Kumar A. (2011 ). Principles and Practice of Geriatric Psychiatry. Hoboken, NJ: Wiley–Blackwell.
Not in our library
6.
Ahmad M. H. Fatima M. Mondal A. C. (2019 ). Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer's disease: rational insights for the therapeutic approaches. J. Clin. Neurosci. 59, 6–11.
Not in our library10.1016/j.jocn.2018.10.034
7.
Alata W. Ye Y. St-Amour I. Vandal M. Calon F. (2015 ). Human apolipoprotein e ε4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J. Cereb. Blood Flow Metab. 35, 86–94.
Not in our library10.1038/jcbfm.2014.172
8.
Alexander J. J. (2018 ). Blood-brain barrier (BBB) and the complement landscape. Mol. Immunol. 102, 26–31.
Not in our library10.1016/j.molimm.2018.06.267
9.
Alkabie S. Basivireddy J. Zhou L. Roskams J. Rieckmann P. Quandt J. A. (2016 ). SPARC expression by cerebral microvascular endothelial cells in vitro and its influence on blood-brain barrier properties. J. Neuroinflammation 13, 1–17.
Not in our library10.1186/s12974-016-0657-9
10.
Allen C. Thornton P. Denes A. McColl B. W. Pierozynski A. Monestier M.. (2012 ). Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J. Immunol.189, 381–392.
Not in our library10.4049/jimmunol.1200409
11.
Alvarez J. I. Dodelet-Devillers A. Kebir H. Ifergan I. Fabre P. J. Terouz S.. (2011 ). The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science334, 1727–1731.
Not in our library10.1126/science.1206936
12.
Anor C. J. O'Connor S. Saund A. Tang-Wai D. F. Keren R. Tartaglia M. C. (2017 ). Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia. Neurodegener. Dis. 17, 127–134.
Not in our library10.1159/000455127
13.
Early neurone loss in Alzheimer’s disease: cortical or subcortical? · 2015
No notice
14.
Aw D. Silva A. B. Palmer D. B. (2007 ). Immunosenescence: emerging challenges for an ageing population. Immunology 120, 435–446.
Not in our library10.1111/j.1365-2567.2007.02555.x
15.
Bake S. Friedman J. A. Sohrabji F. (2009 ). Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc. Res. 78, 413–424.
Not in our library10.1016/j.mvr.2009.06.009
16.
Baker S. K. Chen Z.-L. Norris E. H. Revenko A. S. MacLeod A. R. Strickland S. (2018 ). Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 115, E9687–E9696.
Not in our library10.1073/pnas.1811172115
17.
Ballaed C. Gauthier S. Corbett A. Brayne C. Aarsland D. (2011 ). Jones e. Alzheimer's disease. Lancet 377, 1019–1031.
Not in our library10.1016/s0140-6736(10)61349-9
18.
Banks W. A. Reed M. J. Logsdon A. F. Rhea E. M. Erickson M. A. (2021 ). Healthy aging and the blood-brain barrier. Nature Aging 1, 243–254.
Not in our library10.1038/s43587-021-00043-5
19.
Bannerman D. D. Goldblum S. E. (1999 ). Direct effects of endotoxin on the endothelium: barrier function and injury. Lab. Invest. 79, 1181–1199.
Not in our library
20.
Bartels T. De Schepper S. Hong S. (2020 ). Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. Science 370, 66–69.
Not in our library10.1126/science.abb8587
21.
Bell R. D. Winkler E. A. Sagare A. P. Singh I. LaRue B. Deane R.. (2010 ). Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron68, 409–427.
Not in our library10.1016/j.neuron.2010.09.043
22.
Bell R. D. Winkler E. A. Singh I. Sagare A. P. Deane R. Wu Z.. (2012 ). Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature485, 512–516.
Not in our library10.1038/nature11087
23.
Bell R. D. Zlokovic B. V. (2009 ). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103–113.
Not in our library10.1007/s00401-009-0522-3
24.
Ben-Menachem E. Johansson B. B. Svensson T. (1982 ). Increased vulnerability of the blood-brain barrier to acute hypertension following depletion of brain noradrenaline. J. Neural Transm. 53, 159–167.
Not in our library10.1007/bf01243407
25.
Berezowski V. Landry C. Dehouck M.-P. Cecchelli R. Fenart L. (2004 ). Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res. 1018, 1–9.
Not in our library10.1016/j.brainres.2004.05.092
26.
Bhaskar K. Konerth M. Kokiko-Cochran O. N. Cardona A. Ransohoff R. M. Lamb B. T. (2010 ). Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19–31.
Not in our library10.1016/j.neuron.2010.08.023
27.
Amyloid Triggers Extensive Cerebral Angiogenesis Causing Blood Brain Barrier Permeability and Hypervascularity in Alzheimer's Disease · 2011
No notice
28.
Blanchette M. Daneman R. (2015 ). Formation and maintenance of the BBB. Mech. Dev. 138, 8–16.
Not in our library10.1016/j.mod.2015.07.007
29.
Blau C. W. Cowley T. R. O'Sullivan J. Grehan B. Browne T. C. Kelly L.. (2012 ). The age-related deficit in LTP is associated with changes in perfusion and blood-brain barrier permeability. Neurobiol. Aging33, 1005.e1023–1005.e1035.
Not in our library10.1016/j.neurobiolaging.2011.09.035
30.
NADPH oxidase as a therapeutic target in Alzheimer's disease · 2008
No notice
31.
Boyle P. A. Yu L. Wilson R. S. Leurgans S. E. Schneider J. A. Bennett D. A. (2018 ). Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83, 74–83.
Not in our library10.1002/ana.25123
32.
Brown W. R. Thore C. R. (2011 ). Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol. Appl. Neurobiol. 37, 56–74.
Not in our library10.1111/j.1365-2990.2010.01139.x
33.
Buschini E. Piras A. Nuzzi R. Vercelli A. (2011 ). Age related macular degeneration and drusen: neuroinflammation in the retina. Prog. Neurobiol. 95, 14–25.
Not in our library10.1016/j.pneurobio.2011.05.011
34.
Bussian T. J. Aziz A. Meyer C. F. Swenson B. L. van Deursen J. M. Baker D. J. (2018 ). Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578–582.
Not in our library10.1038/s41586-018-0543-y
35.
Cai W. Zhang K. Li P. Zhu L. Xu J. Yang B.. (2017 ). Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: an aging effect. Ageing Res. Rev.34, 77–87.
Not in our library10.1016/j.arr.2016.09.006
36.
Cai Z. Wan C.-Q. Liu Z. (2017 ). Astrocyte and Alzheimer's disease. J. Neurol. 264, 2068–2074.
Not in our library10.1007/s00415-017-8593-x
37.
Candelario-Jalil E. Thompson J. Taheri S. Grossetete M. Adair J. C. Edmonds E.. (2011 ). Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke42, 1345–1350.
Not in our library10.1161/strokeaha.110.600825
38.
Candiello J. Cole G. J. Halfter W. (2010 ). Age-dependent changes in the structure, composition and biophysical properties of a human basement membrane. Matrix Biol. 29, 402–410.
Not in our library10.1016/j.matbio.2010.03.004
39.
Candore G. Bulati M. Caruso C. Castiglia L. Colonna-Romano G. Di Bona D.. (2010 ). Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res.13, 301–313.
Not in our library10.1089/rej.2009.0993
40.
Carrano A. Hoozemans J. J. van der Vies S. M. Rozemuller A. J. van Horssen J. de Vries H. E. (2011 ). Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid. Redox Signal. 15, 1167–1178.
Not in our library10.1089/ars.2011.3895
41.
Castillo-Gomez E. Kästner A. Steiner J. Schneider A. Hettling B. Poggi G.. (2016 ). The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NR1. Ann. Neurol.79, 144–151.
Not in our library10.1002/ana.24545
42.
The Neuron-Astrocyte-Microglia Triad in Normal Brain Ageing and in a Model of Neuroinflammation in the Rat Hippocampus · 2012
No notice
43.
Chacón-Quintero M. V. Pineda-López L. G. Villegas-Lanau C. A. Posada-Duque R. Cardona-Gómez G. P. (2021 ). Beta-secretase 1 underlies reactive astrocytes and endothelial disruption in neurodegeneration. Front. Cell. Neurosci. 15:656832.
Not in our library10.3389/fncel.2021.656832
44.
Chang H.-C. Guarente L. (2014 ). SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 25, 138–145.
Not in our library10.1016/j.tem.2013.12.001
45.
Chen J. Cui X. Zacharek A. Cui Y. Roberts C. Chopp M. (2011 ). White matter damage and the effect of matrix metalloproteinases in type 2 diabetic mice after stroke. Stroke 42, 445–452.
Not in our library10.1161/strokeaha.110.596486
46.
Cheng T. Petraglia A. L. Li Z. Thiyagarajan M. Zhong Z. Wu Z.. (2006 ). Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med.12, 1278–1285.
Not in our library10.1038/nm1498
47.
Chiu C. Miller M. C. Monahan R. Osgood D. P. Stopa E. G. Silverberg G. D. (2015 ). P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations. Neurobiol. Aging 36, 2475–2482.
Not in our library10.1016/j.neurobiolaging.2015.05.020
48.
Choi D.-H. Kim J.-H. Seo J.-H. Lee J. Choi W. S. Kim Y.-S. (2014 ). Matrix metalloproteinase-3 causes dopaminergic neuronal death through Nox1-regenerated oxidative stress. PLoS ONE 9:e115954.
Not in our library10.1371/journal.pone.0115954
49.
Chow B. W. Gu C. (2015 ). The molecular constituents of the blood-brain barrier. Trends Neurosci. 38, 598–608.
Not in our library10.1016/j.tins.2015.08.003
50.
Chui H. C. Ramirez-Gomez L. (2015 ). Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res. Ther. 7:21.
Not in our library10.1186/s13195-015-0104-7
51.
Cohen Z. Bonvento G. Lacombe P. and Hamel, E. (1996 ). Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 50, 335–362.
Not in our library10.1016/s0301-0082(96)00033-0
52.
Cohen Z. Molinatti G. Hamel E. (1997 ). Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J. Cereb. Blood Flow Metab. 17, 894–904.
Not in our library10.1097/00004647-199708000-00008
53.
Cortes-Canteli M. Mattei L. Richards A. T. Norris E. H. Strickland S. (2015 ). Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol. Aging 36, 608–617.
Not in our library10.1016/j.neurobiolaging.2014.10.030
54.
Cortes-Canteli M. Paul J. Norris E. H. Bronstein R. Ahn H. J. Zamolodchikov D.. (2010 ). Fibrinogen and β-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron66, 695–709.
Not in our library10.1016/j.neuron.2010.05.014
55.
Crews L. Masliah E. (2010 ). Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet. 19, R12–R20.
Not in our library10.1093/hmg/ddq160
56.
Cuevas E. Rosas-Hernandez H. Burks S. M. Ramirez-Lee M. A. Guzman A. Imam S. Z.. (2019 ). Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. Metab. Brain Dis.34, 1365–1374.
Not in our library10.1007/s11011-019-00447-8
57.
D'Ambrosio A. Pontecorvo S. Colasanti T. Zamboni S. Francia A. Margutti P. (2015 ). Peripheral blood biomarkers in multiple sclerosis. Autoimmun. Rev. 14, 1097–1110.
Not in our library10.1016/j.autrev.2015.07.014
58.
De Jong G. Horvath E. Luiten P. (1990 ). Effects of early onset of nimodipine treatment on microvascular integrity in the aging rat brain. Stroke 21(12 Suppl), IV113–IV116.
Not in our library
59.
Deane R. Du Yan S. Submamaryan R. K. LaRue B. Jovanovic S. Hogg E.. (2003 ). RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med.9, 907–913.
Not in our library10.1038/nm890
60.
Deane R. Sagare A. Hamm K. Parisi M. Lane S. Finn M. B.. (2008 ). apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest.118, 4002–4013.
Not in our library10.1172/jci36663
61.
Deane R. Wu Z. Sagare A. Davis J. Du Yan S. Hamm K.. (2004 ). LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron43, 333–344.
Not in our library10.1016/j.neuron.2004.07.017
62.
Deli M. A. Veszelka S. Csiszár B. Tóth A. Kittel A. Csete M.. (2010 ). Protection of the blood-brain barrier by pentosan against amyloid-β-induced toxicity. J. Alzheimers Dis.22, 777–794.
Not in our library10.3233/jad-2010-100759
63.
Di Cataldo V. Géloën A. Langlois J.-B. Chauveau F. Thézé B. Hubert V.. (2016 ). Exercise does not protect against peripheral and central effects of a high cholesterol diet given ad libitum in old ApoE–/– mice. Front. Physiol.7:453.
Not in our library10.3389/fphys.2016.00453
64.
Early Decline in Glucose Transport and Metabolism Precedes Shift to Ketogenic System in Female Aging and Alzheimer's Mouse Brain: Implication for Bioenergetic Intervention · 2013
No notice
65.
Doeuvre L. Plawinski L. Goux D. Vivien D. Anglés-Cano E. (2010 ). Plasmin on adherent cells: from microvesiculation to apoptosis. Biochem. J. 432, 365–373.
Not in our library10.1042/bj20100561
66.
Donahue J. E. Flaherty S. L. Johanson C. E. Duncan J. A. Silverberg G. D. Miller M. C.. (2006 ). RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol.112, 405–415.
Not in our library10.1007/s00401-006-0115-3
67.
Donato A. J. Eskurza I. Silver A. E. Levy A. S. Pierce G. L. Gates P. E.. (2007 ). Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-κB. Circ. Res.100, 1659–1666.
Not in our library10.1161/01.res.0000269183.13937.e8
68.
Du S.-Q. Wang X.-R. Xiao L.-Y. Tu J.-F. Zhu W. He T.. (2017 ). Molecular mechanisms of vascular dementia: what can be learned from animal models of chronic cerebral hypoperfusion?Mol. Neurobiol.54, 3670–3682.
Not in our library10.1007/s12035-016-9915-1
69.
Duncombe J. Lennen R. J. Jansen M. A. Marshall I. Wardlaw J. M. Horsburgh K. (2017 ). Ageing causes prominent neurovascular dysfunction associated with loss of astrocytic contacts and gliosis. Neuropathol. Appl. Neurobiol. 43, 477–491.
Not in our library10.1111/nan.12375
70.
Modifiable Risk Factors for Alzheimer’s Disease · 2019
No notice
71.
Eikelenboom P. Van Exel E. Veerhuis R. Rozemuller A. J. Van Gool W. A. Hoozemans J. J. (2012 ). Innate immunity and the etiology of late-onset Alzheimer's disease. Neurodegener. Dis. 10, 271–273.
Not in our library10.1159/000334287
72.
Blood–brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment · 2015
No notice
73.
Ellison D. White D. Farrar F. C. (2015 ). Aging population. Nurs. Clin. 50, 185–213.
Not in our library10.1016/j.cnur.2014.10.014
74.
Emrani S. Lamar M. Price C. C. Wasserman V. Matusz E. Au R.. (2020 ). Alzheimer's/vascular spectrum dementia: classification in addition to diagnosis. J. Alzheimers Dis.73, 63–71.
Not in our library10.3233/jad-190654
75.
Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle · 2011
No notice
76.
Engelhardt B. Ransohoff R. M. (2012 ). Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 33, 579–589.
Not in our library10.1016/j.it.2012.07.004
77.
Erdo F. Denes L. de Lange E. (2017 ). Age-associated physiological and pathological changes at the blood-brain barrier: a review. J. Cereb. Blood Flow Metab. 37, 4–24.
Not in our library10.1177/0271678x16679420
78.
Erickson M. A. Banks W. A. (2013 ). Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab. 33, 1500–1513.
Not in our library10.1038/jcbfm.2013.135
79.
Erickson M. A. Banks W. A. (2018 ). Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions. Pharmacol. Rev. 70, 278–314.
Not in our library10.1124/pr.117.014647
80.
Erickson M. A. Hansen K. Banks W. A. (2012 ). Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine. Brain Behav. Immun. 26, 1085–1094.
Not in our library10.1016/j.bbi.2012.07.003
81.
Faraco G. Park L. Anrather J. Iadecola C. (2017 ). Brain perivascular macrophages: characterization and functional roles in health and disease. J. Mol. Med. 95, 1143–1152.
Not in our library10.1007/s00109-017-1573-x
82.
Farrall A. J. Wardlaw J. M. (2009 ). Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol. Aging 30, 337–352.
Not in our library10.1016/j.neurobiolaging.2007.07.015
83.
Farrer L. A. Cupples L. A. Haines J. L. Hyman B. Kukull W. A. Mayeux R.. (1997 ). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA278, 1349–1356.
Not in our library10.1001/jama.1997.03550160069041
84.
Fivenson E. M. Lautrup S. Sun N. Scheibye-Knudsen M. Stevnsner T. Nilsen H.. (2017 ). Mitophagy in neurodegeneration and aging. Neurochem. Int.109, 202–209.
Not in our library10.1016/j.neuint.2017.02.007
85.
Fonseca M. I. Ager R. R. Chu S.-H. Yazan O. Sanderson S. D. LaFerla F. M.. (2009 ). Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol.183, 1375–1383.
Not in our library10.4049/jimmunol.0901005
86.
Gao T. Lin Z. Jin X. (2009 ). Hydrocortisone suppression of the expression of VEGF may relate to toll-like receptor (TLR) 2 and 4. Curr. Eye Res. 34, 777–784.
Not in our library10.1080/02713680903067919
87.
Gill R. Tsung A. Billiar T. (2010 ). Linking oxidative stress to inflammation: Toll-like receptors. Free Radic. Biol. Med. 48, 1121–1132.
Not in our library10.1016/j.freeradbiomed.2010.01.006
88.
González-Molina L. A. Villar-Vesga J. Henao-Restrepo J. Villegas A. Lopera F. Cardona-Gómez G. P.. (2021 ). Extracellular vesicles from 3xTg-AD mouse and Alzheimer's disease patient astrocytes impair neuroglial and vascular components. Front. Aging Neurosci.13:593927.
Not in our library10.3389/fnagi.2021.593927
89.
Gonzalez-Velasquez F. J. Kotarek J. A. Moss M. A. (2008 ). Soluble aggregates of the amyloid-β protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J. Neurochem. 107, 466–477.
Not in our library10.1111/j.1471-4159.2008.05618.x
90.
Goodall E. F. Wang C. Simpson J. E. Baker D. J. Drew D. R. Heath P. R.. (2018 ). Age-associated changes in the blood-brain barrier: comparative studies in human and mouse. Neuropathol. Appl. Neurobiol.44, 328–340.
Not in our library10.1111/nan.12408
91.
Goodman R. A. Lochner K. A. Thambisetty M. Wingo T. S. Posner S. F. Ling S. M. (2017 ). Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement. 13, 28–37.
Not in our library10.1016/j.jalz.2016.04.002
92.
Gorelick P. B. Scuteri A. Black S. E. DeCarli C. Greenberg S. M. Iadecola C.. (2011 ). Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42, 2672–2713.
Not in our library10.1161/str.0b013e3182299496
93.
Gredilla R. Bohr V. A. Stevnsner T. (2010 ). Mitochondrial DNA repair and association with aging-an update. Exp. Gerontol. 45, 478–488.
Not in our library10.1016/j.exger.2010.01.017
94.
Grinberg L. T. Heinsen H. (2010 ). Toward a pathological definition of vascular dementia. J. Neurol. Sci. 299, 136–138.
Not in our library10.1016/j.jns.2010.08.055
95.
Grinberg L. T. Thal D. R. (2010 ). Vascular pathology in the aged human brain. Acta Neuropathol. 119, 277–290.
Not in our library10.1007/s00401-010-0652-7
96.
Halliday M. R. Rege S. V. Ma Q. Zhao Z. Miller C. A. Winkler E. A.. (2016 ). Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J. Cereb. Blood Flow Metab.36, 216–227.
Not in our library10.1038/jcbfm.2015.44
97.
Hammer C. Stepniak B. Schneider A. Papiol S. Tantra M. Begemann M.. (2014 ). Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry19, 1143–1149.
Not in our library10.1038/mp.2013.110
98.
Hansen D. V. Hanson J. E. Sheng M. (2018 ). Microglia in Alzheimer's disease. J. Cell Biol. 217, 459–472.
Not in our library10.1083/jcb.201709069
99.
Harry G. J. (2013 ). Microglia during development and aging. Pharmacol. Therapeut. 139, 313–326.
Not in our library10.1016/j.pharmthera.2013.04.013
100.
Dual microglia effects on blood brain barrier permeability induced by systemic inflammation · 2019
No notice
101.
Hase Y. Ding R. Harrison G. Hawthorne E. King A. Gettings S.. (2019 ). White matter capillaries in vascular and neurodegenerative dementias. Acta Neuropathol. Commun.7, 1–12.
Not in our library10.1186/s40478-019-0666-x
102.
Hawkes C. A. Gatherer M. Sharp M. M. Dorr A. Yuen H. M. Kalaria R.. (2013 ). Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain. Aging Cell12, 224–236.
Not in our library10.1111/acel.12045
103.
Hawkins B. T. Davis T. P. (2005 ). The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57, 173–185.
Not in our library10.1124/pr.57.2.4
104.
He H. Lam M. McCormick T. S. Distelhorst C. W. (1997 ). Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J. Cell Biol. 138, 1219–1228.
Not in our library10.1083/jcb.138.6.1219
105.
Heinsen H. Heinsen Y. (1983 ). Cerebellar capillaries. Anat. Embryol. 168, 101–116.
Not in our library10.1007/bf00305402
106.
Heithoff B. P. George K. K. Phares A. N. Zuidhoek I. A. Munoz-Ballester C. Robel S. (2021 ). Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. Glia 69, 436–472.
Not in our library10.1002/glia.23908
107.
Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities · 2019
No notice
108.
Heneka M. T. Carson M. J. El Khoury J. Landreth G. E. Brosseron F. Feinstein D. L.. (2015 ). Neuroinflammation in Alzheimer's disease. Lancet Neurol.14, 388–405.
Not in our library10.1016/s1474-4422(15)70016-5
109.
Hicks P. Rolsten C. Brizzee D. Samorajski T. (1983 ). Age-related changes in rat brain capillaries. Neurobiol. Aging 4, 69–75.
Not in our library10.1016/0197-4580(83)90057-x
110.
Hoarau J.-J. Krejbich-Trotot P. Jaffar-Bandjee M.-C. Das T. Thon-Hon G.-V. Kumar S.. (2011 ). Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol. Disord. Drug Targets10, 25–43.
Not in our library10.2174/187152711794488601
111.
Age Drives Distortion of Brain Metabolic, Vascular and Cognitive Functions, and the Gut Microbiome · 2017
No notice
112.
Hoshi A. Yamamoto T. Shimizu K. Ugawa Y. Nishizawa M. Takahashi H.. (2012 ). Characteristics of aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in Alzheimer disease. J. Neuropathol. Exp. Neurol.71, 750–759.
Not in our library10.1097/nen.0b013e3182632566
113.
The Role of Basement Membranes in Cerebral Amyloid Angiopathy · 2020
Not checked
114.
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms · 2020
No notice
115.
Huber J. D. Campos C. R. Mark K. S. Davis T. P. (2006 ). Alterations in blood-brain barrier ICAM-1 expression and brain microglial activation after λ-carrageenan-induced inflammatory pain. Am. J. Physiol. Heart Circ. Physiol. 290, H732–H740.
Not in our library10.1152/ajpheart.00747.2005
116.
Hughes S. Gardiner T. Hu P. Baxter L. Rosinova E. Chan-Ling T. (2006 ). Altered pericyte-endothelial relations in the rat retina during aging: implications for vessel stability. Neurobiol. Aging 27, 1838–1847.
Not in our library10.1016/j.neurobiolaging.2005.10.021
117.
Hultman K. Strickland S. Norris E. H. (2013 ). The APOE ε4/ε4 genotype potentiates vascular fibrin (ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J. Cereb. Blood Flow Metab. 33, 1251–1258.
Not in our library10.1038/jcbfm.2013.76
118.
Hyman B. T. Phelps C. H. Beach T. G. Bigio E. H. Cairns N. J. Carrillo M. C.. (2012 ). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement.8, 1–13.
Not in our library10.1016/j.jalz.2011.10.007
119.
Iadecola C. (2013 ). The pathobiology of vascular dementia. Neuron 80, 844–866.
Not in our library10.1016/j.neuron.2013.10.008
120.
Iadecola C. (2017 ). The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 96, 17–42.
Not in our library10.1016/j.neuron.2017.07.030
121.
Iadecola C. Davisson R. L. (2008 ). Hypertension and cerebrovascular dysfunction. Cell Metab. 7, 476–484.
Not in our library10.1016/j.cmet.2008.03.010
122.
Ihara M. Polvikoski T. M. Hall R. Slade J. Y. Perry R. H. Oakley A. E.. (2010 ). Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol.119, 579–589.
Not in our library10.1007/s00401-009-0635-8
123.
Iliff J. J. Wang M. Liao Y. Plogg B. A. Peng W. Gundersen G. A.. (2012 ). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med.4:147ra111.
Not in our library10.1126/scitranslmed.3003748
124.
Imai S.-I. Guarente L. (2014 ). NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24, 464–471.
Not in our library10.1016/j.tcb.2014.04.002
125.
Jack C. (2010 ). Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res. Rev. 9, 218–225.
Not in our library10.1016/j.arr.2010.04.002
126.
Jacob A. Alexander J. J. (2014 ). Complement and blood-brain barrier integrity. Mol. Immunol. 61, 149–152.
Not in our library10.1016/j.molimm.2014.06.039
127.
Jaeger L. Dohgu S. Sultana R. Lynch J. Owen J. Erickson M.. (2011 ). Lipopolysaccharide alters the blood-brain barrier transport of amyloid β protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav. Immun.23, 507–517.
Not in our library10.1016/j.bbi.2010.11.019
128.
Jiang T. Yin F. Yao J. Brinton R. D. Cadenas E. (2013 ). Lipoic acid restores age-associated impairment of brain energy metabolism through the modulation of A kt/JNK signaling and PGC 1α transcriptional pathway. Aging Cell 12, 1021–1031.
Not in our library10.1111/acel.12127
129.
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity · 2020
No notice
130.
Kalaria R. (2002 ). Similarities between Alzheimer's disease and vascular dementia. J. Neurol. Sci. 203, 29–34.
Not in our library10.1016/s0022-510x(02)00256-3
131.
Kang S. Lee Y.-H. Lee J. E. (2017 ). Metabolism-centric overview of the pathogenesis of Alzheimer's disease. Yonsei Med. J. 58, 479–488.
Not in our library10.3349/ymj.2017.58.3.479
132.
Kettenmann H. Hanisch U.-K. Noda M. Verkhratsky A. (2011 ). Physiology of microglia. Physiol. Rev. 91, 461–553.
Not in our library10.1152/physrev.00011.2010
133.
Khan M. B. Hoda M. N. Vaibhav K. Giri S. Wang P. Waller J. L.. (2015 ). Remote ischemic postconditioning: harnessing endogenous protection in a murine model of vascular cognitive impairment. Transl. Stroke Res.6, 69–77.
Not in our library10.1007/s12975-014-0374-6
134.
Kimbrough I. F. Robel S. Roberson E. D. Sontheimer H. (2015 ). Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. Brain 138, 3716–3733.
Not in our library10.1093/brain/awv327
135.
Kinnecom C. Lev M. Wendell L. Smith E. Rosand J. Frosch M.. (2007 ). Course of cerebral amyloid angiopathy-related inflammation. Neurology68, 1411–1416.
Not in our library10.1212/01.wnl.0000260066.98681.2e
136.
Kirshner H. S. (2009 ). Vascular dementia: a review of recent evidence for prevention and treatment. Curr. Neurol. Neurosci. Rep. 9, 437–442.
Not in our library10.1007/s11910-009-0065-y
137.
Kofler J. Wiley C. A. (2011 ). Microglia: key innate immune cells of the brain. Toxicol. Pathol. 39, 103–114.
Not in our library10.1177/0192623310387619
138.
Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide · 2011
No notice
139.
Kovac A. Zilkova M. Deli M. A. Zilka N. Novak M. (2009 ). Human truncated tau is using a different mechanism from amyloid-β to damage the blood-brain barrier. J. Alzheimers Dis. 18, 897–906.
Not in our library10.3233/jad-2009-1197
140.
Functional Impairment of Microglia Coincides with Beta-Amyloid Deposition in Mice with Alzheimer-Like Pathology · 2013
No notice
141.
Ageing, Cellular Senescence and Neurodegenerative Disease · 2018
No notice
142.
A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease · 2021
No notice
143.
Lan Y.-L. Zhao J. Ma T. Li S. (2016a ). The potential roles of aquaporin 4 in Alzheimer's disease. Mol. Neurobiol. 53, 5300–5309.
Not in our library10.1007/s12035-015-9446-1
144.
Lan Y.-L. Zou S. Chen J.-J. Zhao J. Li S. (2016b ). The neuroprotective effect of the association of aquaporin-4/glutamate transporter-1 against Alzheimer's disease. Neural Plast. 2016:4626593.
Not in our library10.1155/2016/4626593
145.
Lapenna A. De Palma M. Lewis C. E. (2018 ). Perivascular macrophages in health and disease. Nat. Rev. Immunol. 18, 689–702.
Not in our library10.1038/s41577-018-0056-9
146.
Lassman M. E. McLaughlin T. M. Somers E. P. Stefanni A. C. Chen Z. Murphy B. A.. (2012 ). A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom.26, 101–108.
Not in our library10.1002/rcm.5296
147.
Lee P. Kim J. Williams R. Sandhir R. Gregory E. Brooks W. M.. (2012 ). Effects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice. Exp. Neurol.234, 50–61.
Not in our library10.1016/j.expneurol.2011.12.016
148.
Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes · 2019
No notice
149.
Leng F. Edison P. (2020 ). Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157–172.
Not in our library10.1038/s41582-020-00435-y
150.
Levit A. Hachinski V. Whitehead S. N. (2020 ). Neurovascular unit dysregulation, white matter disease, and executive dysfunction: the shared triad of vascular cognitive impairment and Alzheimer disease. GeroScience 42, 445–465.
Not in our library10.1007/s11357-020-00164-6
151.
Li W. Lai X.-S. (2007 ). Changes of interleukin-1beta and TNF-alpha contents in the hippocampus and the interventional effect of electroacupuncture in vascular dementia rats. Zhen Ci Yan Jiu 32, 34–37.
Not in our library
152.
Li W. Z. Wu W. Y. Huang H. Wu Y. Y. Yin Y. Y. (2013 ). Protective effect of bilobalide on learning and memory impairment in rats with vascular dementia. Mol. Med. Rep. 8, 935–941.
Not in our library10.3892/mmr.2013.1573
153.
Lin Y.-F. Smith A. V. Aspelund T. Betensky R. A. Smoller J. W. Gudnason V.. (2019 ). Genetic overlap between vascular pathologies and Alzheimer's dementia and potential causal mechanisms. Alzheimers Dement.15, 65–75.
Not in our library10.1016/j.jalz.2018.08.002
154.
Liu C.-C. Kanekiyo T. Xu H. Bu G. (2013 ). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106–118.
Not in our library10.1038/nrneurol.2012.263
155.
Liu H. Zhang J. (2012 ). Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. Int. J. Neurosci. 122, 494–499.
Not in our library10.3109/00207454.2012.686543
156.
Lucke-Wold B. P. Logsdon A. F. Turner R. C. Rosen C. L. Huber J. D. (2014 ). Aging, the metabolic syndrome, and ischemic stroke: redefining the approach for studying the blood-brain barrier in a complex neurological disease. Adv. Pharmacol. 71, 411–449.
Not in our library10.1016/bs.apha.2014.07.001
157.
Månberg A. Skene N. Sanders F. Trusohamn M. Remnestål J. Szczepińska A.. (2021 ). Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med.27, 640–646.
Not in our library10.1038/s41591-021-01295-9
158.
Ma X. Sun Z. Liu Y. Jia Y. Zhang B. Zhang J. (2013 ). Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia. Neural Regen. Res. 8, 2050–2059.
Not in our library10.3969/j.issn.1673-5374.2013.22.004
159.
Matthes F. Matuskova H. Arkelius K. Ansar S. Lundgaard I. Meissner A. (2021 ). An improved method for physical separation of cerebral vasculature and parenchyma enables detection of blood-brain-barrier dysfunction. NeuroSci 2, 59–74.
Not in our library10.3390/neurosci2010004
160.
Mattson M. P. Magnus T. (2006 ). Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7, 278–294.
Not in our library10.1038/nrn1886
161.
Mazzieri R. Masiero L. Zanetta L. Monea S. Onisto M. Garbisa S.. (1997 ). Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J.16, 2319–2332.
Not in our library10.1093/emboj/16.9.2319
162.
Merlini M. Rafalski V. A. Coronado P. E. R. Gill T. M. Ellisman M. Muthukumar G.. (2019 ). Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer's disease model. Neuron101, 1099.e6–1108.e6.
Not in our library10.1016/j.neuron.2019.01.014
163.
Middeldorp J. Hol E. (2011 ). GFAP in health and disease. Prog. Neurobiol. 93, 421–443.
Not in our library10.1016/j.pneurobio.2011.01.005
164.
Miller M. C. Tavares R. Johanson C. E. Hovanesian V. Donahue J. E. Gonzalez L.. (2008 ). Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res.1230, 273–280.
Not in our library10.1016/j.brainres.2008.06.124
165.
Mills S. Cain J. Purandare N. Jackson A. (2007 ). Biomarkers of cerebrovascular disease in dementia. Brit. J. Radiol. 80, S128–S145.
Not in our library10.1259/bjr/79217686
166.
CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology · 2019
No notice
167.
Monea S. Lehti K. Keski-Oja J. Mignatti P. (2002 ). Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol. 192, 160–170.
Not in our library10.1002/jcp.10126
168.
Montagne A. Barnes S. R. Sweeney M. D. Halliday M. R. Sagare A. P. Zhao Z.. (2015 ). Blood-brain barrier breakdown in the aging human hippocampus. Neuron85, 296–302.
Not in our library10.1016/j.neuron.2014.12.032
169.
Montagne A. Nation D. A. Sagare A. P. Barisano G. Sweeney M. D. Chakhoyan A.. (2020 ). APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature581, 71–76.
Not in our library10.1038/s41586-020-2247-3
170.
Montagne A. Nikolakopoulou A. M. Zhao Z. Sagare A. P. Si G. Lazic D.. (2018 ). Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat. Med.24, 326–337.
Not in our library10.1038/nm.4482
171.
Mooradian A. Chung H. Shah G. (1997 ). GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol. Aging 18, 469–474.
Not in our library10.1016/s0197-4580(97)00111-5
172.
Morris A. W. Carare R. O. Schreiber S. Hawkes C. A. (2014 ). The cerebrovascular basement membrane: role in the clearance of β-amyloid and cerebral amyloid angiopathy. Front. Aging Neurosci. 6:251.
Not in our library10.3389/fnagi.2014.00251
173.
Nation D. A. Sweeney M. D. Montagne A. Sagare A. P. D'Orazio L. M. Pachicano M.. (2019 ). Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med.25, 270–276.
Not in our library10.1038/s41591-018-0297-y
174.
Nelson A. R. Sweeney M. D. Sagare A. P. Zlokovic B. V. (2016 ). Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochim. Biophys. Acta 1862, 887–900.
Not in our library10.1016/j.bbadis.2015.12.016
175.
Nicholls D. G. Budd S. L. (2000 ). Mitochondria and neuronal survival. Physiol. Rev. 80, 315–360.
Not in our library10.1152/physrev.2000.80.1.315
176.
Niego B. E. Freeman R. Puschmann T. B. Turnley A. M. Medcalf R. L. (2012 ). t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 119, 4752–4761.
Not in our library10.1182/blood-2011-07-369512
177.
Nikolakopoulou A. M. Montagne A. Kisler K. Dai Z. Wang Y. Huuskonen M. T.. (2019 ). Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat. Neurosci.22, 1089–1098.
Not in our library10.1038/s41593-019-0434-z
178.
Nikolakopoulou A. M. Wang Y. Ma Q. Sagare A. P. Montagne A. Huuskonen M. T.. (2021 ). Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. J. Exp. Med.218:e20202207.
Not in our library10.1084/jem.20202207
179.
Nishitsuji K. Hosono T. Nakamura T. Bu G. Michikawa M. (2011 ). Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J. Biol. Chem. 286, 17536–17542.
Not in our library10.1074/jbc.m111.225532
180.
Aβ1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation · 2000
Not checked
181.
Obermeier B. Daneman R. Ransohoff R. M. (2013 ). Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19, 1584–1596.
Not in our library10.1038/nm.3407
182.
O'Brien T. Thomas J. A. (2015 ). Vascular dementia. Lancet 386, 1698–1706.
Not in our library10.1016/s.0140-6736(15)00463-8
183.
O'Connell G. C. Treadway M. B. Petrone A. B. Tennant C. S. Lucke-Wold N. Chantler P. D.. (2017 ). Peripheral blood AKAP7 expression as an early marker for lymphocyte-mediated post-stroke blood brain barrier disruption. Sci. Rep.7, 1–13.
Not in our library10.1038/s41598-017-01178-5
184.
Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis · 2014
No notice
185.
Owen J. B. Sultana R. Aluise C. D. Erickson M. A. Price T. O. Bu G.. (2010 ). Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain. Free Radic. Biol. Med.49, 1798–1803.
Not in our library10.1016/j.freeradbiomed.2010.09.013
186.
Pan W. P Stone K. Hsuchou H. K Manda V.. (2011 ). Cytokine signaling modulates blood-brain barrier function. Curr. Pharm. Des.17, 3729–3740.
Not in our library10.2174/138161211798220918
187.
Park H. R. Park M. Choi J. Park K.-Y. Chung H. Y. Lee J. (2010 ). A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci. Lett. 482, 235–239.
Not in our library10.1016/j.neulet.2010.07.046
188.
Park L. Uekawa K. Garcia-Bonilla L. Koizumi K. Murphy M. Pistik R.. (2017 ). Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer Aβ peptides. Circ. Res.121, 258–269.
Not in our library10.1161/circresaha.117.311054
189.
Park M. H. Lee J. Y. Park K. H. Jung I. K. Kim K.-T. Lee Y.-S.. (2018 ). Vascular and neurogenic rejuvenation in aging mice by modulation of ASM. Neuron100, 167.e9–182.e9.
Not in our library10.1016/j.neuron.2018.09.010
190.
Patching S. G. (2017 ). Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol. Neurobiol. 54, 1046–1077.
Not in our library10.1007/s12035-015-9672-6
191.
Patterson C. (2018 ). World Alzheimer Report 2018.
Not in our library
192.
Peinado M. A. Quesada A. Pedrosa J. A. Torres M. I. Martinez M. Esteban F. J.. (1998 ). Quantitative and ultrastructural changes in glia and pericytes in the parietal cortex of the aging rat. Microsc. Res. Tech.43, 34–42.
Not in our library10.1002/(sici)1097-0029(19981001)43:1<34::aid-jemt6>3.0.co;2-g
193.
Alzheimer Disease and Oxidative Stress · 2002
No notice
194.
Peters A. Josephson K. Vincent S. L. (1991 ). Effects of aging on the neuroglial cells and pericytes within area 17 of the rhesus monkey cerebral cortex. Anat. Rec. 229, 384–398.
Not in our library10.1002/ar.1092290311
195.
Pilozzi A. Carro C. Whalen M. Huang X. (2020 ). “Blood-brain barrier degradation and the implication of SPARC protein as a potential therapeutic target for Alzheimer's disease,” in Alzheimer's Disease: Drug Discovery, ed X. Huang (Brisbane, QLD: Exon Publications), 135–149.
Not in our library10.36255/exonpublications.alzheimersdisease.2020.ch8
196.
Price B. R. Norris C. M. Sompol P. Wilcock D. M. (2018 ). An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia. J. Neurochem. 144, 644–650.
Not in our library10.1111/jnc.14273
197.
Quaegebeur A. Lange C. Carmeliet P. (2011 ). The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 71, 406–424.
Not in our library10.1016/j.neuron.2011.07.013
198.
Raja R. Rosenberg G. A. Caprihan A. (2018 ). MRI measurements of blood-brain barrier function in dementia: a review of recent studies. Neuropharmacology 134, 259–271.
Not in our library10.1016/j.neuropharm.2017.10.034
199.
Rajan A. M. Ma R. C. Kocha K. M. Zhang D. J. Huang P. (2020 ). Dual function of perivascular fibroblasts in vascular stabilization in zebrafish. PLoS Genet. 16:e1008800.
Not in our library10.1371/journal.pgen.1008800
200.
Rajani R. M. Quick S. Ruigrok S. R. Graham D. Harris S. E. Verhaaren B. F.. (2018 ). Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats. Sci. Transl. Med.10:eaam9507.
Not in our library10.1126/scitranslmed.aam9507
201.
Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1 · 2015
No notice
202.
Ramos-DeSimone N. Hahn-Dantona E. Sipley J. Nagase H. French D. L. Quigley J. P. (1999 ). Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274, 13066–13076.
Not in our library10.1074/jbc.274.19.13066
203.
Ransohoff R. M. Engelhardt B. (2012 ). The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 12, 623–635.
Not in our library10.1038/nri3265
204.
Rascher G. Wolburg H. (2002 ). “The blood-brain barrier in the aging brain.” in Neuroglia in the Aging Brain, ed J. S. de Vellis (Totowa, NJ: Humana Press), 305–320.
Not in our library10.1385/1-59259-105-1:305
205.
Rasmussen M. K. Mestre H. Nedergaard M. (2018 ). The glymphatic pathway in neurological disorders. Lancet Neurol. 17, 1016–1024.
Not in our library10.1016/s1474-4422(18)30318-1
206.
Ray L. Khemka V. K. Behera P. Bandyopadhyay K. Pal S. Pal K.. (2013 ). Serum homocysteine, dehydroepiandrosterone sulphate and lipoprotein (a) in Alzheimer's disease and vascular dementia. Aging Dis.4, 57–64.
Not in our library
207.
Reeson P. Choi K. Brown C. E. (2018 ). VEGF signaling regulates the fate of obstructed capillaries in mouse cortex. Elife 7:e33670.
Not in our library10.7554/elife.33670.029
208.
Reuter B. Rodemer C. Grudzenski S. Meairs S. Bugert P. Hennerici M. G.. (2015 ). Effect of simvastatin on MMPs and TIMPs in human brain endothelial cells and experimental stroke. Transl. Stroke Res.6, 156–159.
Not in our library10.1007/s12975-014-0381-7
209.
Reyahi A. Nik A. M. Ghiami M. Gritli-Linde A. Pontén F. Johansson B. R.. (2015 ). Foxf2 is required for brain pericyte differentiation and development and maintenance of the blood-brain barrier. Dev. Cell34, 19–32.
Not in our library10.1016/j.devcel.2015.05.008
210.
Richardson K. C. M Stephan B. G Ince P. Brayne C.. (2012 ). The neuropathology of vascular disease in the medical research council cognitive function and ageing study (MRC CFAS). Curr. Alzheimer Res.9, 687–696.
Not in our library10.2174/156720512801322654
211.
Rivard A. Berthou-Soulie L. Principe N. Kearney M. Curry C. Branellec D.. (2000 ). Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J. Biol. Chem.275, 29643–29647.
Not in our library10.1074/jbc.m001029200
212.
Ronaldson T. Davis P. (2012 ). Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr. Pharm. Des. 18, 3624–3644.
Not in our library10.2174/138161212802002625
213.
Rosenberg G. (2014 ). Blood-brain barrier permeability in aging and Alzheimer's disease. J. Prevent. Alzheimers Dis. 1, 138–139.
Not in our library10.14283/2fjpad.2014.25
214.
Rosenberg G. A. (2012 ). Neurological diseases in relation to the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1139–1151.
Not in our library10.1038/jcbfm.2011.197
215.
Rosenberg G. A. (2017 ). Extracellular matrix inflammation in vascular cognitive impairment and dementia. Clin. Sci. 131, 425–437.
Not in our library10.1042/cs20160604
216.
Rosenberg G. A. Yang Y. (2007 ). Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg. Focus 22, 1–9.
Not in our library10.3171/foc.2007.22.5.5
217.
Roudnicky F. Zhang J. D. Kim B. K. Pandya N. J. Lan Y. Sach-Peltason L.. (2020 ). Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells. Proc. Nat. Acad. Sci. U.S.A.117, 19854–19865.
Not in our library10.1073/pnas.1911532117
218.
Rouhl R. P. Damoiseaux J. G. Lodder J. Theunissen R. O. Knottnerus I. L. Staals J.. (2012 ). Vascular inflammation in cerebral small vessel disease. Neurobiol. Aging33, 1800–1806.
Not in our library10.1016/j.neurobiolaging.2011.04.008
219.
Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation · 2015
No notice
220.
Ryu J. K. Rafalski V. A. Meyer-Franke A. Adams R. A. Poda S. B. Coronado P. E. R.. (2018 ). Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat. Immunol.19, 1212–1223.
Not in our library10.1038/s41590-018-0232-x
221.
Sabayan B. Jansen S. Oleksik A. M. van Osch M. J. van Buchem M. A. van Vliet P.. (2012 ). Cerebrovascular hemodynamics in Alzheimer's disease and vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res. Rev.11, 271–277.
Not in our library10.1016/j.arr.2011.12.009
222.
Sachdev P. Kalaria R. O'Brien J. Skoog I. Alladi S. Black S. E.. (2014 ). Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis. Assoc. Disord.28, 206–218.
Not in our library10.1097/wad.0000000000000034
223.
Sagare A. Deane R. Bell R. D. Johnson B. Hamm K. Pendu R.. (2007 ). Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med.13, 1029–1031.
Not in our library10.1038/nm1635
224.
Sagare A. P. Bell R. D. Zhao Z. Ma Q. Winkler E. A. Ramanathan A.. (2013 ). Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun.4, 1–14.
Not in our library10.1038/ncomms3932
225.
Sagare A. P. Bell R. D. Zlokovic B. V. (2012 ). Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:a011452.
Not in our library10.1101/cshperspect.a011452
226.
Sagare A. P. Sweeney M. D. Makshanoff J. Zlokovic B. V. (2015 ). Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes. Neurosci. Lett. 607, 97–101.
Not in our library10.1016/j.neulet.2015.09.025
227.
Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia · 2016
No notice
228.
Salmina A. B. Inzhutova A. I. Malinovskaya N. A. Petrova M. M. (2010 ). Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control. J. Alzheimers Dis. 22, 17–36.
Not in our library10.3233/jad-2010-091690
229.
Salminen A. Ojala J. Kaarniranta K. Haapasalo A. Hiltunen M. Soininen H. (2011 ). Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur. J. Neurosci. 34, 3–11.
Not in our library10.1111/j.1460-9568.2011.07738.x
230.
Sanchez-Covarrubias L. Slosky L. M. Thompson B. J. Davis T. P. Ronaldson P. T. (2014 ). Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr. Pharm. Des. 20, 1422–1449.
Not in our library10.2174/13816128113199990463
231.
Schneider J. A. Arvanitakis Z. Leurgans S. E. Bennett D. A. (2009 ). The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200–208.
Not in our library10.1002/ana.21706
232.
Schultz N. Brännström K. Byman E. Moussaud S. Nielsen H. M. Bank N. B.. (2018 ). Amyloid-beta 1-40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro. Aging Cell17:e12728.
Not in our library10.1111/acel.12728
233.
Sengillo J. D. Winkler E. A. Walker C. T. Sullivan J. S. Johnson M. Zlokovic B. V. (2013 ). Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol. 23, 303–310.
Not in our library10.1111/bpa.12004
234.
Silbert L. C. Dodge H. H. Perkins L. G. Sherbakov L. Lahna D. Erten-Lyons D.. (2012 ). Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology79, 741–747.
Not in our library10.1212/wnl.0b013e3182661f2b
235.
Simpkins A. N. Dias C. Leigh R. Benson R. T. Hsia A. W. Latour L. L.. (2016 ). Identification of reversible disruption of the human blood-brain barrier following acute ischemia. Stroke47, 2405–2408.
Not in our library10.1161/strokeaha.116.013805
236.
Simpson J. Ince P. Haynes L. Theaker R. Gelsthorpe C. Baxter L.. (2010 ). Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Neuropathol. Appl. Neurobiol.36, 25–40.
Not in our library10.1111/j.1365-2990.2009.01030.x
237.
Skillbäck T. Delsing L. Synnergren J. Mattsson N. Janelidze S. Nägga K.. (2017 ). CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol. Aging59, 1–9.
Not in our library10.1016/j.neurobiolaging.2017.06.028
238.
Sloane P. D. Zimmerman S. Suchindran C. Reed P. Wang L. Boustani M.. (2002 ). The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu. Rev. Public Health23, 213–231.
Not in our library10.1146/annurev.publhealth.23.100901.140525
239.
APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction · 2015
No notice
240.
Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging · 2019
Not checked
241.
Stewart P. Magliocco M. Hayakawa K. Farrell C. Del Maestro R. Girvin J.. (1987 ). A quantitative analysis of blood-brain barrier ultrastructure in the aging human. Microvasc. Res.33, 270–282.
Not in our library10.1016/0026-2862(87)90022-7
242.
Storck S. E. Meister S. Nahrath J. Meißner J. N. Schubert N. Di Spiezio A.. (2016 ). Endothelial LRP1 transports amyloid-β 1-42 across the blood-brain barrier. J. Clin. Invest.126, 123–136.
Not in our library10.1172/jci81108
243.
Stranahan A. M. Norman E. D. Lee K. Cutler R. G. Telljohann R. S. Egan J. M.. (2008 ). Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus18, 1085–1088.
Not in our library10.1002/hipo.20470
244.
Stratman A. N. Schwindt A. E. Malotte K. M. Davis G. E. (2010 ). Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood 116, 4720–4730.
Not in our library10.1182/blood-2010-05-286872
245.
Strunz M. Jarrell J. T. Cohen D. S. Rosin E. R. Vanderburg C. R. Huang X. (2019 ). Modulation of SPARC/Hevin proteins in Alzheimer's disease brain injury. J. Alzheimers Dis. 68, 695–710.
Not in our library10.3233/jad-181032
246.
Sturrock R. (1980 ). A comparative quantitative and morphological study of ageing in the mouse neostriatum, indusium griseum and anterior commissure. Neuropathol. Appl. Neurobiol. 6, 51–68.
Not in our library10.1111/j.1365-2990.1980.tb00204.x
247.
Sumi N. Nishioku T. Takata F. Matsumoto J. Watanabe T. Shuto H.. (2010 ). Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. Cell. Mol. Neurobiol.30, 247–253.
Not in our library10.1007/s10571-009-9446-7
248.
Suzuki Y. Nagai N. Yamakawa K. Kawakami J. Lijnen H. R. Umemura K. (2009 ). Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood 114, 3352–3358.
Not in our library10.1182/blood-2009-02-203919
249.
Sweeney M. D. Ayyadurai S. Zlokovic B. V. (2016 ). Pericytes of the neurovascular unit: key functions and signaling pathways. Nat. Neurosci. 19, 771–783.
Not in our library10.1038/nn.4288
250.
Sweeney M. D. Kisler K. Montagne A. Toga A. W. Zlokovic B. V. (2018a ). The role of brain vasculature in neurodegenerative disorders. Nat. Neurosci. 21, 1318–1331.
Not in our library10.1038/s41593-018-0234-x
251.
Sweeney M. D. Montagne A. Sagare A. P. Nation D. A. Schneider L. S. Chui H. C.. (2019a ). Vascular dysfunction-the disregarded partner of Alzheimer's disease. Alzheimers Dement.15, 158–167.
Not in our library10.1016/j.jalz.2018.07.222
252.
Sweeney M. D. Sagare A. P. Pachicano M. Harrington M. G. Joe E. Chui H. C.. (2020 ). A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimers Dement.16, 821–830.
Not in our library10.1002/alz.12061
253.
Sweeney M. D. Sagare A. P. Zlokovic B. V. (2018b ). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133–150.
Not in our library10.1038/nrneurol.2017.188
254.
Sweeney M. D. Zhao Z. Montagne A. Nelson A. R. Zlokovic B. V. (2019b ). Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78.
Not in our library10.1152/physrev.00050.2017
255.
Tachibana M. Holm M.-L. Liu C.-C. Shinohara M. Aikawa T. Oue H.. (2019 ). APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1. J. Clin. Invest.129, 1272–1277.
Not in our library10.1172/jci124853
256.
Tada M. Diserens A.-C. Desbaillets I. de Tribolet N. (1994 ). Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J. Neurosurg. 80, 1063–1073.
Not in our library10.3171/jns.1994.80.6.1063
257.
Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α, releasing matrix metalloproteinase-9 and migrating in vitro · 2011
No notice
258.
Tan Z. Jiang J. Tian F. Peng J. Yang Z. Li S.. (2020 ). Serum visinin-like protein 1 is a better biomarker than neuron-specific enolase for seizure-induced neuronal injury: a prospective and observational study. Front. Neurol.11:567587.
Not in our library10.3389/fneur.2020.567587
259.
Tarumi T. Zhang R. (2018 ). Cerebral blood flow in normal aging adults: cardiovascular determinants, clinical implications, and aerobic fitness. J. Neurochem. 144, 595–608.
Not in our library10.1111/jnc.14234
260.
Tayler H. Miners J. S. Güzel Ö. MacLachlan R. Love S. (2021 ). Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer's disease, vascular dementia and mixed dementia. Brain Pathol. 31:e12935.
Not in our library10.1111/bpa.12935
261.
Thal D. R. Grinberg L. T. Attems J. (2012 ). Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp. Gerontol. 47, 816–824.
Not in our library10.1016/j.exger.2012.05.023
262.
Tibbling G. Link H. Öhman S. (1977 ). Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 37, 385–390.
Not in our library10.3109/00365517709091496
263.
Tomimoto H. Akiguchi I. Suenaga T. Nishimura M. Wakita H. Nakamura S.. (1996 ). Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke27, 2069–2074.
Not in our library10.1161/01.str.27.11.2069
264.
Tong X. Hamel E. (1999 ). Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92, 163–175.
Not in our library10.1016/s0306-4522(98)00750-7
265.
Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia · 2020
No notice
266.
Ueno M. Akiguchi I. Hosokawa M. Shinnou M. Sakamoto H. Takemura M.. (1998 ). Ultrastructural and permeability features of microvessels in the olfactory bulbs of SAM mice. Acta Neuropathol.96, 261–270.
Not in our library10.1007/s004010050893
267.
Ueno M. Tomimoto H. Akiguchi I. Wakita H. Sakamoto H. (2002 ). Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J. Cereb. Blood Flow Metab. 22, 97–104.
Not in our library10.1097/00004647-200201000-00012
268.
P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender · 2012
No notice
269.
Van De Haar H. J. Burgmans S. Jansen J. F. Van Osch M. J. Van Buchem M. A. Muller M.. (2016 ). Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology281, 527–535.
Not in our library10.1148/radiol.2016152244
270.
Vasic V. Barth K. Schmidt M. H. (2019 ). Neurodegeneration and neuro-regeneration-Alzheimer's disease and stem cell therapy. Int. J. Mol. Sci. 20, 4272.
Not in our library10.3390/ijms20174272
271.
Vaucher E. Tong X. K. Cholet N. Lantin S. Hamel E. (2000 ). GABA neurons provide a rich input to microvessels but not nitric oxide neurons in the rat cerebral cortex: a means for direct regulation of local cerebral blood flow. J. Compar. Neurol. 421, 161–171.
Not in our library10.1002/(sici)1096-9861(20000529)421:2<161::aid-cne3>3.0.co;2-f
272.
Veerhuis R. Nielsen H. M. Tenner A. J. (2011 ). Complement in the brain. Mol. Immunol. 48, 1592–1603.
Not in our library10.1016/j.molimm.2011.04.003
273.
Verhaaren B. F. Vernooij M. W. de Boer R. Hofman A. Niessen W. J. van der Lugt A.. (2013 ). High blood pressure and cerebral white matter lesion progression in the general population. Hypertension61, 1354–1359.
Not in our library10.1161/hypertensionaha.111.00430
274.
Increase in blood–brain barrier leakage in healthy, older adults · 2020
No notice
275.
Verma S. Nakaoke R. Dohgu S. Banks W. A. (2006 ). Release of cytokines by brain endothelial cells: a polarized response to lipopolysaccharide. Brain Behav. Immun. 20, 449–455.
Not in our library10.1016/j.bbi.2005.10.005
276.
Villar-Vesga J. Henao-Restrepo J. Voshart D. C. Aguillon D. Villegas A. Castaño D.. (2020 ). Differential profile of systemic extracellular vesicles from sporadic and familial Alzheimer's disease leads to neuroglial and endothelial cell degeneration. Front. Aging Neurosci.12:587989.
Not in our library10.3389/fnagi.2020.587989
277.
Villeda S. A. Luo J. Mosher K. I. Zou B. Britschgi M. Bieri G.. (2011 ). The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature477, 90–94.
Not in our library10.1038/nature10357
278.
Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia · 2018
No notice
279.
Wang W. Lv S. Zhou Y. Fu J. Li C. Liu P. (2011 ). Tumor necrosis factor-α affects blood-brain barrier permeability in acetaminophen-induced acute liver failure. Eur. J. Gastroenterol. Hepatol. 23, 552–558.
Not in our library10.1097/meg.0b013e3283470212
280.
Wang X. Lee S.-R. Arai K. Lee S.-R. Tsuji K. Rebeck G. W.. (2003 ). Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med.9, 1313–1317.
Not in our library10.1038/nm926
281.
Interleukin-1β Induces Blood–Brain Barrier Disruption by Downregulating Sonic Hedgehog in Astrocytes · 2014
No notice
282.
Wangb C. L. A. Wuc Y. Gulbinsc E. Grassméc H. Zhaoa Z. (2019 ). Acid sphingomyelinase-ceramide system in bacterial infections. Cell. Physiol. Biochem. 52, 280–301.
Not in our library10.33594/000000021
283.
Wardlaw J. Sandercock P. Dennis M. Starr J. (2003 ). Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34, 806–812.
Not in our library10.1161/01.str.0000058480.77236.b3
284.
Wharton S. B. Brayne C. Savva G. M. Matthews F. E. Forster G. Simpson J.. (2011 ). Epidemiological neuropathology: the MRC cognitive function and aging study experience. J. Alzheimers Dis.25, 359–372.
Not in our library10.3233/jad-2011-091402
285.
Winkler E. A. Bell R. D. Zlokovic B. V. (2011 ). Central nervous system pericytes in health and disease. Nat. Neurosci. 14, 1398–1405.
Not in our library10.1038/nn.2946
286.
Winkler E. A. Nishida Y. Sagare A. P. Rege S. V. Bell R. D. Perlmutter D.. (2015 ). GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat. Neurosci.18, 521–530.
Not in our library10.1038/nn.3966
287.
Won J.-S. Kim J. Annamalai B. Shunmugavel A. Singh I. Singh A. K. (2013 ). Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion. J. Alzheimers Dis. 34, 621–635.
Not in our library10.3233/jad-121786
288.
Wu F. Zou Q. Ding X. Shi D. Zhu X. Hu W.. (2016 ). Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J. Neuroinflammation13, 1–14.
Not in our library10.1186/s12974-016-0485-y
289.
Xiao M. Xiao Z. J. Yang B. Lan Z. Fang F. (2020 ). Blood-brain barrier: more contributor to disruption of central nervous system homeostasis than victim in neurological disorders. Front. Neurosci. 14:764.
Not in our library10.3389/fnins.2020.00764
290.
Yamazaki Y. Shinohara M. Shinohara M. Yamazaki A. Murray M. E. Liesinger A. M.. (2019 ). Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression. Brain142, 1077–1092.
Not in our library10.1093/brain/awz011
291.
Yang C. Huang X. Huang X. Mai H. Li J. Jiang T.. (2016 ). Aquaporin-4 and Alzheimer's disease. J. Alzheimers Dis.52, 391–402.
Not in our library10.3233/jad-150949
292.
Yang J. Lunde L. K. Nuntagij P. Oguchi T. Camassa L. Nilsson L. N.. (2011 ). Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease. J. Alzheimers Dis.27, 711–722.
Not in our library10.3233/jad-2011-110725
293.
Yang T. Guo R. Zhang F. (2019 ). Brain perivascular macrophages: recent advances and implications in health and diseases. CNS Neurosci. Therapeut. 25, 1318–1328.
Not in our library10.1111/cns.13263
294.
Yang W. Wu Q. Yuan C. Gao J. Xiao M. Gu M.. (2012 ). Aquaporin-4 mediates astrocyte response to β-amyloid. Mol. Cell. Neurosci.49, 406–414.
Not in our library10.1016/j.mcn.2012.02.002
295.
Yang Y. Hill J. W. Rosenberg G. A. (2011 ). Multiple roles of metalloproteinases in neurological disorders. Prog. Mol. Biol. Transl. Sci. 99, 241–263.
Not in our library10.1016/b978-0-12-385504-6.00006-3
296.
Yang Y. Kimura-Ohba S. Thompson J. F. Salayandia V. M. Cosse M. Raz L.. (2018 ). Vascular tight junction disruption and angiogenesis in spontaneously hypertensive rat with neuroinflammatory white matter injury. Neurobiol. Dis.114, 95–110.
Not in our library10.1016/j.nbd.2018.02.012
297.
Yao Y. Chen Z.-L. Norris E. H. Strickland S. (2014 ). Astrocytic laminin regulates pericyte differentiation and maintains blood brain barrier integrity. Nat. Commun. 5, 1–12.
Not in our library10.1038/ncomms4413
298.
Yepes M. Woo Y. Martin-Jimenez C. (2021 ). Plasminogen activators in neurovascular and neurodegenerative disorders. Int. J. Mol. Sci. 22:4380.
Not in our library10.3390/ijms22094380
299.
Neurovascular Unit Dysfunction and Neurodegenerative Disorders · 2020
No notice
300.
Zeevi N. Pachter J. McCullough L. D. Wolfson L. Kuchel G. A. (2010 ). The blood-brain barrier: geriatric relevance of a critical brain-body interface. J. Am. Geriatr. Soc. 58, 1749–1757.
Not in our library10.1111/j.1532-5415.2010.03011.x
301.
Zenaro E. Piacentino G. Constantin G. (2017 ). The blood-brain barrier in Alzheimer's disease. Neurobiol. Dis. 107, 41–56.
Not in our library10.1016/j.nbd.2016.07.007
302.
Zenaro E. Pietronigro E. Della Bianca V. Piacentino G. Marongiu L. Budui S.. (2015 ). Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med.21, 880–886.
Not in our library10.1038/nm.3913
303.
Zeppenfeld D. M. Simon M. Haswell J. D. D'Abreo D. Murchison C. Quinn J. F.. (2017 ). Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol.74, 91–99.
Not in our library10.1001/jamaneurol.2016.4370
304.
Zhang X. Wu B. Nie K. Jia Y. Yu J. (2014 ). Effects of acupuncture on declined cerebral blood flow, impaired mitochondrial respiratory function and oxidative stress in multi-infarct dementia rats. Neurochem. Int. 65, 23–29.
Not in our library10.1016/j.neuint.2013.12.004
305.
Zhao Z. Nelson A. R. Betsholtz C. Zlokovic B. V. (2015 ). Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064–1078.
Not in our library10.1016/j.cell.2015.10.067
306.
Zhao Z. Ong L. K. Johnson S. Nilsson M. Walker F. R. (2017 ). Chronic stress induced disruption of the peri-infarct neurovascular unit following experimentally induced photothrombotic stroke. J. Cereb. Blood Flow Metab. 37, 3709–3724.
Not in our library10.1177/0271678x17696100
307.
TGFβ signalling plays an important role in IL4-induced alternative activation of microglia · 2012
No notice
308.
Zhu H.-Y. Hong F.-F. Yang S.-L. (2021 ). The roles of nitric oxide synthase/nitric oxide pathway in the pathology of vascular dementia and related therapeutic approaches. Int. J. Mol. Sci. 22:4540.
Not in our library10.3390/ijms22094540
309.
Zlokovic B. V. (2005 ). Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202–208.
Not in our library10.1016/j.tins.2005.02.001
310.
Zlokovic B. V. (2011 ). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723–738.
Not in our library10.1038/nrn3114
311.
Zonneveld H. I. Goos J. D. Wattjes M. P. Prins N. D. Scheltens P. van der Flier W. M.. (2014 ). Prevalence of cortical superficial siderosis in a memory clinic population. Neurology82, 698–704.
Not in our library10.1212/wnl.0000000000000150
312.
Zotova E. Holmes C. Johnston D. Neal J. W. Nicoll J. A. Boche D. (2011 ). Microglial alterations in human Alzheimer's disease following Aβ42 immunization. Neuropathol. Appl. Neurobiol. 37, 513–524.
Not in our library10.1111/j.1365-2990.2010.01156.x

Cited by papers we hold 5

Role of Oxidative Stress in Blood–Brain Barrier Disruption and Neurodegenerative Diseases · 2024
No notice
WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective · 2023
No notice
Astrocyte Involvement in Blood–Brain Barrier Function: A Critical Update Highlighting Novel, Complex, Neurovascular Interactions · 2023
No notice
Mechanisms of Short-Chain Fatty Acids Derived from Gut Microbiota in Alzheimer's Disease · 2022
No notice
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System · 2022
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.